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1. Introduction
1.1 Oral Controlled Drug Delivery System
Pharmaceutical  technologists  today  are  able  to  provide  drug  delivery 
system with very precise control over drug release for a prolonged period of time, 
eliminating  need  for  frequent  dosing  and  minimizing  side  effect  and  increasing 
patient compliance and comfort.
The history of controlled drug delivery  technologies spans  over  five 
decades since the introduction of the SpansuleR1 formulation by Smith   Kline And 
French  Laboratories  in  1952  (www.gsk.com/about/background.htm)  for  the  first 
controlled-release  delivery  over  the  past  two decades,  have  been significant.  The 
ability to control the drug release kinetics is such that drug delivery for days  and 
years can be achieved. Since the first book on controlled drug delivery was published 
in 1978, drug delivery has advanced significantly.
At the beginning of 2004, a keyword search on controlled drug delivery 
using the Scifinder scholar database would have resulted in 9,612 references. Figure 
No.1 shows the  number  of  publications  since  1970.  As can  be  seen,  research  on 
controlled drug delivery has continued a steady rise until the second half of 1990s. 
Research in  the 1980s was focused mainly on mathematical  modeling  on various 
types of controlled drug delivery system, and clear understandings on how to control 
the release kinetics may have contributed to the explosive growth of   the controlled-
release technology area throughout the past ten years. It is difficult to read all those 
past publications even only for abstracts. It is desirable to have a single volume that 
summarizes  work  done  from  past  to  present  using  comprehensive  and  coherent 
information on controlled-release dosage forms. Such a book does becomes available 
once every decades or so! Examples are Novel Drug Delivery System, second Edition 
published in 1992, and Modified Release Drug Delivery Technology published in 
2003. 
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Figure No.1 Number of Publications on Controlled Drug Delivery System
In the  recent    past,  controlled  release  concept  and technology have  received 
increasing attention in the face of growing awareness to toxicity and ineffectiveness of 
drugs. When drugs are administered in the form of conventional drug delivery system, 
usually produce wide ranging fluctuations in drug concentration in the blood stream and 
tissues and consequently leads to undesirable toxicity and inefficiency.  This factor, as 
well   as other factors such as repetitive dosing and unpredictable absorption, led to the 
concept of controlled drug delivery systems or therapeutic system.
As controlled   drug delivery advances further, the pharmaceutical industry has 
realized that    the introduction of new delivery technologies  would extend the patent 
protection of their drugs. Such an incentive provides significant motives for investment in 
this lucrative area. Despite extensive research in drug   delivery,  the advances in oral 
application  have  been  relatively  slow.  Some  of  the  scientific  challenges  and opinion 
about the oral controlled drug delivery systems are discussed in the coming paragraphs.
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Scientific Challenges in Oral Drug Delivery Technologies 
While  the  oral  route  is  the  most  convenient  method  of  drug  administration, 
advances   in oral drug delivery technologies have been limited. One of the reasons for 
this is the limitations imposed by the unique gastro intestinal physiology illustrated in 
Figure No.2 In these areas, even small improvements in drug delivery technology can 
make significant differences in enhancing patient compliance and drug bioavailability.
Figure No.2 Physiology of Gastrointestinal Tract
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Formulation for Ease of Administration (Oral Delivery)
It is estimated that approximately one-third of the population has pill-swallowing 
difficulties, primarily the geriatric and pediatric populations. The geriatric and pediatric 
populations are more prone to have swallowing difficulties.  It is common to see those 
afflicted carrying a small device with them, which is used for crushing tablets, enabling 
easy ingestion. To alleviate the problems associated with swallowing difficulties, a new 
dosage form, known as fast-dissolving tablets, has been developed. Since 1986 when the 
Zydis  R Lyophilized,  fast-dissolving  dosage  form were first  introduced,  a  number  of 
other fast-dissolving formulation were developed, and the technology is still improving. 
The fast-dissolving tablets are also called fast-melt or fast disintegrating.  And one more 
dosage form for controlled release of drug is developed called as Gastro Retentive Drug 
Delivery System.
Gastric Retention Platform
One of  the  "holy  grails"  in  oral  drug  delivery  is  to  develop  gastric  retention 
platform  for  long-term  (ranging  from  6  to  24  hours)  delivery  of  drugs  by  oral 
administration.  Currently, there are a number of drugs that can be delivered using once-
daily formulations. This is possible only for drugs that are well absorbed throughout the 
GI tract or typically have long terminal elimination half-lives. There are a large number 
of drug that are not absorbed to the same extend once they pass the upper small intestine,  
and thus, once-daily formulations are elusive for the drugs. One method to overcome the 
fast GI transit is maintain the dosage form in the stomach for extended  period of time, 
and therefore,  research efforts  have been focused on development  of gastric retention 
platforms.
One of the 9,612 references found in controlled drug delivery (Figure No.1) 1,683 
references were on oral drug delivery, but only 20 were on gastric retention on particular 
topics.  Clearly,  the progress on developing gastric retention platforms has been show 
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Table No.1 lists some of the approaches that have been applied to the development of 
gastric retention platforms.
Only a small number of companies are actively working on their development. 
This is mainly due to the inherent difficulty associated with achieving gastric retention. 
The lack  of  a  suitable  in  vitro  model  to  study gastric  retention  has  compounded  the 
problem.  To alleviate  this  problem,  an  in  vitro  model  designed to  mimic  the  gastric 
retention of oral dosage forms is under development.
TableNo.1 Approaches for making Gastric Retention Platforms
S No Technology Website
1 Low  density  micro  spheres  with 
bioadhesive coats
www.westpharma.com
2 Moderately swelling matrix system www.depomedinc.com
3. Bioadhesives www.kypharmaceutical.com
4. Super swelling hydro gel system www.kospharm.com
   One of the major scientific challenges in the development of gastric retention 
devices is overcoming the housekeeping waves that consist of strong gastric contraction 
that  occur  every  few hours,  particularly  in  the  fasted  stated.  If  the  gastric  retention 
technology is based on swelling or expansion of the system, this then must be sufficient  
to maintain the delivery system in the stomach in the fasted condition. The extensive 
swelling or expansion; however tends to result in mechanically weak properties, which 
may not withstand the compression exerted by the housekeeper waves. For this reason, 
fast  swelling  hydro  gel  with  mechanically  strong  and  elastic  polymers  have  been 
developed.
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1.2 GASTRO RETENTIVE DRUG DELIVERY SYSTEM
Introduction to Gastric Retention2
Over the past three decades the pursuit and exploration of devices designed to be 
retained in the upper part of the gastrointestinal (GI) tract has advanced consistently in 
term of technology and diversity, encompassing a variety of systems and devices such as 
floating systems, raft system, expanding systems, swelling systems, bioadhesive system 
and low-density systems.
Gastric  retention  will  provide  advantages  such  as  the  delivery  of  drugs  with 
narrow absorption windows in the small intestinal region. Also, longer residence time in 
the  stomach  could  be  advantageous  for  local  action  in  the  upper  part  of  the  small 
intestine,  for  example  treatment  of  peptic  ulcer  disease.   Furthermore,  improved 
bioavailability is expected for drugs that are absorbed readily upon release in the Gastro 
intestinal tract. These drugs can be delivered ideally by slow release from the stomach.
Many drugs categorized as once-a-delivery have been demonstrated to have sub 
optimal absorption due to dependence on thee transit time of the dosage form, making 
traditional extended release development challenging.  Therefore, a system designed for 
longer gastric retention will extend the time within drug absorption can occur in the small 
intestine. There are certain situations where gastric retention is not desirable.
Aspirin  and non-steroidal  anti-inflammatory  drugs  are  known to cause  gastric 
lesions, and slow release of such drugs in the stomach is unwanted.  Thus, drugs that may 
irritate  the  stomach  lining  or  are  unstable  in  its  acidic  environment  should  not  be 
formulated in gastro retentive systems.  Certain types  of drugs can benefit  form using 
gastric retentive s devices.
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These include:
 Drugs acting locally in the stomach,
 Drugs that are primarily absorbed in the stomach,
 Drug those are poorly soluble at an alkaline pH,
 Drugs with a narrow window of absorption,
 Drugs that degrade in the colon,
Physiology of the stomach
The GI tract is essentially a tube about nine meters long that runs through the 
middle  of  the  body  from the  mouth  to  the  anus  and  includes  the  throat  (Pharynx), 
oesophagus, and stomach, small intestine (Consisting of the duodenum and ileum) anus 
large intestine (consisting of the cecum, colon and rectum). The wall of the GI tract has 
the same general structure throughout most of its length. The Stomach is an organ with a 
capacity for the mixing and grinding of gastric contents. Under fasting conditions, the 
stomach is a collapsed bag with a residual volume of approximately 50 ml and contains a 
small  amount  of  gastric  fluid  (pH  1-3)  and  air.  The  mucus  spreads  and  covers  the 
mucosal surface of the stomach as well as the rest of the GI tract. The GI tract is in a state 
of  continuous  motility  consisting  of  two  modes:  interdigestive  motility  pattern  and 
digestive motility pattern.   The former is dominant  in the fasted state with a primary 
function of cleaning up the residual content of the upper GI tract. 
 The  interdigestive  motility  pattern  is  commonly  called  the  ‘migrating  motor 
complex’ (‘MMC’) and is organized in cycles of activity and quiescence each cycle lasts 
90-120 minutes and consists of four phases. The concentration of the hormone motilin in 
the blood controls the duration of the phases. In the interdigestive or fasted state,  an 
MMC wave migrates form the stomach down the GI tract every 90-120 minutes. A full 
cycle  consists  of  four  phases,  beginning  in  the  lower  oesophageal  sphincter/gastric 
pacemaker,  propagating  over  the  whole  stomach,  the  duodenum  and  jejunum,  and 
finishing at  the  ileum.  Phase  III  is  termed  the  ‘housekeeper  waves’  as  the  powerful 
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contractions and indigestible debris. The administration and subsequent ingestion of food 
rapidly interrupts the MMC cycles, and the digestive phase is allowed to take place. The 
upper  part  of  the  stomach  stores  the  ingested  food  initially,  where  it  is  compressed 
gradually by the phasic contraction.
 The digestive or fed state is observed in response to meal ingestion. It resembles 
the fasting Phase II and is not cyclical, but continuous, provided that the food remains in 
the stomach.   Large objects are retained by the stomach during the fed pattern but are 
allowed  to  pass  during  Phase  III  of  the  interdigestive  MMC. It  is  throughout  that  the 
sieving efficacy (i.e. the ability of the stomach to grind the food into smaller size) of the 
stomach is enhanced by the fed pattern and/or by the presence of food. The fasted-state 
emptying pattern is independent of the presence of any indigestible solids in the stomach. 
Patterns of contraction in the stomach occur such that solid food is reduced to particles of 
less than 1mm diameter that are emptied through the pylorus as suspensions. The duration 
of the contractions is dependent on the physiochemical characteristics of the ingested meal. 
Generally, a meal of 450 kcal will interrupt the fasted state motility for about three to four 
hours. It is reported that the antral contractions reduce the size of food particles to ≤1 mm 
and prople the food through the pylorus. However, it has been shown that ingestible solids 
equal’s to ≤7 mm can empty from the fed stomach in humans.
Figure No.3 Anatomical Sketch of Stomach
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Physiology of Gastric Emptying
Before going into the  requirements  of   gastric  retention,  we should  know the 
physiology of gastric emptying.  There are two distinct modes (i.e. fasted and fed) of 
gastrointestinal  motility  that  consumes food in humans  and animals.  In fed state,  the 
stomach handles liquids and solid materials in different ways. Liquid are emptied first 
within  30  minutes  by the  slow and sustained  contractions  of  proximal  stomach.  The 
gastric emptying time of solids meal depends on the type, nutrition density, quality, and 
particle size of the meal. It can be extended to over 14 hours, if fed state conditions are  
maintained.  Particles  less  than  5mm  in  diameter  are  known  to  be  emptied  by  the 
contraction of the distal stomach following the emptying of liquids. Emptying of the solid 
digestible food particles larger than 5 mm is delayed until they are reduced in size by the 
grinding action  of  the stomach.   Indigestible  solids  larger  than  5mm in diameter  are 
retained  within  the  stomach  until  the  digestive  process  is  completed.   The  gastric 
emptying time for regular meal is about 2-6 hours.
Table No.2 The Transit Time Of Different Dosage Forms
Dosage Form
Transit Time (h)
Gastric Small intestine Total
Tablets 2.7±1.5 3.1±0.4 5.8
Pellets 1.2±1.3 3.4±1.0 4.6
Capsules 0.8±1.2 3.2±0.8 4.0
Oral solution 0.3±0.07 4.1±0.5 4.4
The emptying of large indigestible objects from the stomach is dependent on the 
contraction of the interdigestive migration motor complex (IMMC). The IMMC, which 
occurs in the fasted state, (i.e. the state in which the liquids and digestible solids foods 
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been  cleared  from  the  stomach  completely),  is  characterized  by  three  phase  of 
myoelectric and motor activity.
Phase- I: Represented by the period of motor inactivity with only rare contraction lasts 
about 45 - 60 minutes.
Phase-II: Marked with random peristaltic activity with increased frequency and  
amplitude, lasts for over 30 - 45 minutes periods.
Phase-III:  The  active  front  represents  the  intense  burst  of  action  potentials  and 
contractions with continue for 5 - 10 minutes.
This  powerful  electromechanical  activity  of  phase III  sweeps slowly from the 
stomach to the ileum and is responsible for emptying of indigestible debris left over from 
a meal.  This is called the housekeeper wave of the GIT. The gastric emptying time for 
the conventional non-disintegrating dosages forms is mainly determined by the pattern 
occurs every 120 minutes in fast humans.  Under the fasted condition, the gastric empty 
time of insoluble drug formulation is usually 1-2 hours. Consequently, for once a day oral 
drug delivery to be feasible, the gastric retention device must be constructed to overcome 
the peristaltic contraction associated with phase III of  the IMMC.
Requirement for Gastric Retention
From the discussion of the physiological factors in the stomach, it must be noted 
that, to achieve gastric retention, the dosage form must satisfy certain requirements.  One 
of the key issues is that the dosage from  must be able to with stand the forces caused by 
peristaltic waves in the stomach and the constant  contraction and grinding and churning 
mechanisms to function as a gastric  retention  device,  it  must  resist  premature  gastric 
emptying. Furthermore, once its purpose has been served, the devices should be removed 
from the stomach with case.
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Approaches to Gastric Retention
Various approaches have been followed to encourage gastric retention of an oral 
dosage form.  Floating system has low bulk density so that they can float on the gastric 
juice in the stomach.  The problem arises when the stomach is completely emptied of 
gastric fluid.  In such a situation, there is nothing to float on.
Figure No.4 Various Approaches to Gastric Retention
Floating Systems Can Be Based on The Following:
 Hydro dynamically balanced system
             Incorporated buoyant materials enable the device to float.
 Effervescent system
Gas-generating materials such as carbonates are incorporated. These 
materials react with gastric fluid and produce carbon dioxide, which 
allows them to float.
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  Low density system
Low-density system has a density lower than that of the gastric fluid 
so they are buoyant.
 Biodhesive or mucoadhesive system 
These  system  permit  a  given  drug  delivery  system  to  be 
incorporated with bio/muco adhesive agents, enabling the device to 
adhere  to  the  stomach  (or  other  GI)  wall,  thus  resisting  gastric 
emptying. However, the mucus on the walls of the stomach is in a 
state of constant renewal, resulting in unpredictable adherence.   
Multifarious Uses of Gastro Retentive Drug Delivery Systems3
Gastro retentive drug delivery system extends significantly the period of time over 
which the drug may be released. Thus, they not only prolong dosing interval, but also 
increase patient compliance beyond the level of existing controlled release dosage 
forms. This Gastro retentive dosage forms can be used carriers for drugs with so-
called absorption window.  These substances, for example antiviral, antifungal and 
antibiotic  agent  (sulphonamides,  quinolones,  penicillin's,  cephalosporin's,  amino 
glycosides and tetracycline etc., are taken up only from very specific sites of the GI 
mucosa. In addition, by continually supplying the drug to its most efficient site of 
absorption, the dosage forms allow for more effective oral use peptide and protein 
drugs such as calcitonin, erythropoietin, vasopressin, insulin, low-molecular-weight 
heparin, protease inhibitors and luteinising releasing hormone analogues.
Mechanistic Aspects of Gastro Retentive Drug Delivery Systems
Various attempts have been made to retain the dosage form in the stomach as a 
way of increasing the retention time.  This attempt includes introducing floating dosage 
forms  (Gas-generating  systems  and  Swelling  or  expanding  system),  mucoadhesive 
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systems,  high-density  system,  modified  shape  systems,  gastric-emptying  delaying 
devices.   Among  these,  the  floating  dosage  forms  have  been  used  most  commonly. 
However, most of these approaches are influenced by a number of factors that affect their 
efficacy as gastro retentive system.
Factors affecting gastric retention 
1. Density
Gastric residence time is a function of dosage form buoyancy that is 
dependent on the density.
2.  Shape of  dosage form
 Tetrahedron and ring shaping devices with flexural modulus of 48 and 22.5 kilo 
pounds per square inch (KSI) are reported to have better Gastric residence time 90 to 
100percent retention at 24 hours compared with other shapes.
3. Single or multiple unit formulation
Multiple unit formulation show a more predictable release profile and insignificant 
impairing of performance due to failure of units, allow co-administration of units with 
different release profile or containing incompatible substances and permit a larger 
margin of safety against dosage form failure compared with single unit dosage forms.
4. Fed or unfed state
Under  fasting  conditions,  the  GI  motility  is  characterized  by  periods  of 
strong motor  activity  or  the  migration  myoelectric  complex  (MMC) that 
occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the 
stomach and, if the timing of administration of the formulation coincides 
with that the MMC, the GRT of the unit can be expected to be very short. 
However, in the fed state, MMC is delayed and GRT is considerably longer.
5. Nature of meal
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Feeding of indigestible polymer or fatty acid salts can change the motility 
pattern of the stomach to a fed state, thus decreasing the gastric emptying 
rate and prolonging drug release, caloric content Gastric residence time can 
be increased by four to ten hours with a meal that is high in protein and fat
6. Frequency of feed
The  gastric  residence  time  can  increase  by  over  400  minutes  when 
successive  meals  are  given compared with a  single meal  due to  the low 
frequency   of   MMC.
7. Gender
Mean ambulatory GRT in males (3.4+0.6 hours) is less compared with their 
age and race matched female counterparts 4.6 ± 1.2 hours, regardless of the 
weight, height and body surface.
8. Age
Elderly people, especially those over 70, have a significantly     longer GRT
9. Posture
GRT can vary between supine and upright ambulatory state of the patient.
10. Concomitant drug administration
Anti-cholinergics like atropine and propantheline opiates like codeine and prokinetics 
agents like metoclopramide and cisapride.
11. Biological factors
Diabetes and Crohn's disease, etc.,
1.3 TYPES   OF    GASTRO    RETENTIVE     SYSTEMS
Floating Drug Delivery Systems3
Floating drug delivery systems (FDDS) have a bulk density less than gastric fluids 
and so remain buoyant in the stomach without affecting the gastric emptying rate for 
a prolonged period of time. While the system is floating on the gastric contents, the 
drug is released slowly at the desired rate from the system. After release of drug, the 
residual system is emptied from the stomach. This results in an increased GRT and a 
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better control of the fluctuations in plasma drug concentration.  However, besides a 
minimal  gastric  content  needed to allow the proper  achievement  of the  buoyancy 
retention principle, a minimal level of floating force ( F ) is also  required to keep the 
dosage form reliably buoyant on the surface of the meal. To  measure the floating 
force kinetics, a novel apparatus for determination of resultant weight (RW) has been 
reported in the literature.  The RW apparatus operates by measuring continuously the 
force  equivalent  to  F  (as  a  function  of  time)  that  is  required  to  maintain  the 
submerged  object.  The  object  in  optimizing  FDDS  with  respect  to  stability  and 
durability  of  floating  forces  produced  in  order  to  prevent  the  drawbacks  of 
unforeseeable intragastric buoyancy capability.
             
  RW or F = F buoyancy - F gravity   = (Df  - Ds)  gV
Where
                    RW       - Total vertical force,
Df         - Fluid density,
Ds        - Object density,
V          - Volume of the fluid,
g   - Acceleration due to gravity,
Figure No .5 The Mechanism of Floating System
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The FDDS Can Be Divided Into Two Different Categories
                
Non-effervescent systems-The device can float in the stomach due to    swelling of the 
polymer and get density lower than that of gastric content.
Effervescent systems  - The device can float in the stomach due to gas-forming 
agents.
Non-Effervescent Systems
The most commonly used excipients in non-effervescent FDDS are gel forming or 
highly  swellable  cellulose-type  hydrocolloids,  polysaccharides,  and  matrix  forming 
polymers, such as polycarbonate, polyacrylate, polymethaacrylate, and polystyrene. One 
of the approaches  to the formulation of such floating dosage forms involves intimate 
mixing of the drug with a gel-forming hydrocolloid, which swells in contact with gastric 
fluid  after  oral  administration  and maintains  a  relative  integrity  of  shape  and a  bulk 
density  of  less  than  unity within the  outer  gelatinous  barrier.  The air  trapped by the 
swollen polymer confers buoyancy to these dosage forms. In addition, the gel structure 
acts  as  a  reservoir  for  sustained  release  because  the  drug  is  slowly  released  by  a 
controlled diffusion through the gelatinous barrier.
 Sheth and Tossounian postulated that when such dosage forms come in contact 
with an aqueous medium, the hydrocolloid starts to hydrate by first forming a gel at the 
surface that controls the rate of diffusion of solvent in and drug out of the dosage forms. 
Sheth  and  Tossounian  developed  SR  floating  tablets  that  hydro  dynamically 
balanced in the stomach for an extended period of time until all the drug loading dose. 
Tablets were composed of   an active ingredient   and one or more hydrocolloids, such as 
methylcellulose, hydroxy ethyl cellulose, and sodium car boxy methylcellulose, which up 
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on contact with the gastric fluid provided water impermeable colloid gels barriers on the 
surface of the tablets.
 Harrigan  described  an  intragastric  floating  drug  delivery  device,  which  was 
composed of a drug reservoir encapsulated in a micro porous compartment having pores 
along its top and bottom surfaces. The peripheral wall of the drug reservoir compartment 
was completely sealed to prevent any physical contact of the undissolved drug with the 
stomach wall. The floating chamber caused the system to float in the gastric fluid. 
Kamel  et.al., developed floating microspheres of ketoprofen using different ratios 
of Eudragit S 100 and Eudragit RL 100 by emulsion solvent diffusion technique. 
 Lee et.al,.  Studied effected  of non-volatile  oil  as  a  core material  for  floating 
microspheres Eudragit S 100 prepared by emulsion solvent evaporation method. They 
reported  that  microsphers  prepared   without  non-volatile  oil  releases  the  drug  faster 
compared with formulation with non-volatile oil. 
Joseph et al developed a floating-type oral dosage of piroxicom based on hollow 
polycarbonate microspheres and performed in vitro and in vivo evaluation in rabbits. I et 
al studied the effect of hydroxymethylcellulose and carbopol on the release and floating 
properties of gastric floating drug delivery systems using factorial design. Strubel et al 
developed floating micro spheres based on low-density polypropylene foam powder.  
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Figure No.6 The Mechanism of Non-effervescent Floating System
 
Effervescent System
            These buoyant systems utilize matrices prepared with swellable polymer like 
methocel,  polysaccharides  like  chitosan,  effervescent  components  like  sodium 
bicarbonate, citric acid and tartaric acid for chamber containing a liquid that gasifies at 
body temperature.  The common  approach  for  preparing  these  systems  involves  resin 
beads loaded with bicarbonate and coated with ethyl cellulose.  The coating, which is 
insoluble but permeable,  allows permeation of water. Thus, carbondioxied is released, 
causing the beads to float in the stomach (Figure No.5).Other approaches the material 
that have been reported   are   highly swellable hydrocolloids and light mineral oils, a 
mixture of sodium alginates and sodium bicarbonate, a multiple unit floating pills that 
generate  carbondioxide  when  ingested,  floating  mini  capsule  with  a  core  of  sodium 
bicarbonate, microcrystalline cellulose and polyvinyl pyrrolidone coated with hydroxyl 
propyl  methyl  cellulose and floating systems based on ion exchange resin technology 
etc.,
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Recent  developments  include  use  of  super  porous  hydro  gels  that  expand 
dramatically (hundreds of times their dehydrated form within a matter of seconds) when 
immersed in  water.  Oral  drug delivery formulations  made from the gels would swell 
rapidly in the stomach to the intestines and be absorbed more efficiently by the body.
Table No .3 Drug Reported to Be Used in the Formulations of Floating 
Dosage Forms4
S. No Dosage Form Model Drugs
1. Floating micro spheres Ketoprofen, Piroxicam, Verapamil HCl, 
Cholestyramine, Tranilast, Ibuprofen, Aspirin, 
Griesofulvin, and p-Nitroaniline, Terfenadine, 
Theophylline, Ketoprofen, Cinnaxicam, and 
Tenaxicam, Riboflavin, ,Salicylic acid, 
Ethoxybenzamide,, Acetohydroxamic acid.
2. Floating granules Diclofenac  sodium,  Indomethacin  and 
Prednisolone
3. Floating capsules  Misoprostol, Chlordiazepoxide Hcl, Propranolol 
Hcl, Diazepam, Furosemide, Misoprostol, 
L-Dopa and Benserazide, Ursodeoxycholic acid 
4. Floating tablets Theophylline, Chlopheneramine maleate, 
Acetaminophen, Acetylsalicylic acid, Ampicillin, 
Amoxycillin trihydrate, Riboflavin-5-phosphate 
Isosorbide di nitrate, Atenolol,   Diltiazem, 
Fluorouracil, Isosorbide mononitrate, Para-
benzoic acid, Piretamide,Theophylline and 
Verapamil Hcl 
5. Floating Pellets Verapamil and Nor-verapamil
6. Floating Powders Several basic drugs
25
Excipients used most commonly in these systems include HPMC, Polyacrylate 
polymer,  polyvinyl  acetate,  Carbopol,  Agar  Sodium  alginate  Calcium  chloride, 
Polyethylene oxide and Polycarbonates.
Table No.4 Marketed Products of GRDDS 4
S.No Brand  Name Delivery System Drug(with dose) Company 
Country
1. Madopar Floating CR 
Capsules
Benserazide(25mg), 
L-Dopa(100mg)
Roche 
Products,USA
2. Valrelease Floating Capsules Diezepam(15 mg) Hoffmann-
LaRoche,USA
3. Liuqid 
Gaviscon 
Effervescent 
floating liquid 
alginate preparation
Al hydroxide(95mg)
Mg carbonate 
(358mg)
Glaxo 
SmithKline, India
4. Topalkan Floating liquid 
alginate preparation
Al-Mg antacid Pierre Fabre 
Drug, France.
5 Almagate 
Float Coat
Floating dosage 
form
Al-Mg antacid
-
6. Conviron Colloidal gel 
forming FDDS
Ferrous sulphate Ranbaxy, India
7. Cifran OD Gas-generating 
floating form
Ciprofloxacin(1gm) Ranbaxy, India
8. Cytotec Bilayer floating 
capsule
Misprostol(100mcg/
200mcg)
Pharmacia,
USA
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Bio Adhesive Systems
Bioadhesive drug delivery systems (BDDS) are used to localize a delivery device 
within the lumen to enhance the drug absorption in site-specific manner. This approach 
involves the use of bioadhesive polymers, which can adhere to the epithelial surface in 
the  stomach.  A  microbalance-based  system  is  reported  for  measuring  the  forces  of 
interaction between the GI mucosa and the individual polymers, and the Cahn Dynamic 
contact  Angle Analyzer  has been used to study the adherence.  Gastric  mucoadhesion 
does not tend to be strong enough to impart the dosage forms the ability to resist the 
strong propulsion forces of the stomach wall. The continuous production of mucous by 
the gastric mucosa to replace the mucous that is lost through peristaltic contractions and 
the dilution of the stomach content also seem to limit the potential of mucoadhesion as a 
gastro  retentive  force.  Some  of  the  most  promising  excipents  that  have  been  used 
commonly in these systems include polycarbophil, carbopol, lectin, chitosan, CMC and 
gliadin, etc., Some investigators have tried out a synergistic approach between floating 
and bioadhesion systems. Other approaches reported include used of a novel adhesive 
material derived from the fimbriae (Especially Type1) of bacteria or synthetic analogues 
combined with a drug to provide for attachment to the gut, thereby prolonging the transit 
time,  a  composition  comprising  a  n  active  ingredient  and  a  material  that  acts  as  a 
visogenic agent (for example curdlan and/or a low substituted hydroxypropylcellulose) 
etc.,
High-Density Systems
Sedimentation has been employed as a retention mechanism for pellets that are 
small enough to be retained in the rugae or folds of the stomach body near the pyloric 
region, which is part of the organ with the lowest position in an upright posture. Dense 
pellets  (approximately  3  g/cm3)  trapped in rugae  also  ten  to  withstand the  peristaltic 
movements of the stomach wall. With pellets the GI transit time can be extended from an 
average of 5.8 - 25 hours, depending more on density than on diameter of the pellets, 
although many conflicting reports stating otherwise also abound in literature. Commonly 
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used excipents are barium sulphate, Zinc oxide, titanium dioxide and iron powder etc. 
These materials increase density by up to 1.5 - 2.4 g/cm3. However, no successful high-
density system has made it to the market.
Large Single- Unit Dosage Form with Special Shapes
These dosage forms are larger than the pyloric opening and so are retained in the 
stomach. Certain elastomers or plastics made from polyethylene or nylon could increase 
the gastric retention time. Tetrahedrons (each leg 2 cm in length) and ring (3.6 cm in 
diameter) provided gastric retention than 24 hours. These dosage forms, however, were 
neither  digestible  nor  easy  to  load  and  release  drugs.  There  are  some  drawbacks 
associated with this approach permanent retention of rigid large-sized single-unit forms 
can cause bowel obstruction, intestinal adhesion and gastroplasty
Magnetic Dosage Forms
This type of dosage forms is formulated by mixing with ferrite powder with other 
excipients.  After  administration,  these  tablets  were  retained  in  the  stomach  by  an 
externally  applied  strong  magnetic  field.  The  strong  magnetic  field,  however,  is  not 
readily available in practical use.
Balloon Devices
These devices comprises  of collapsed envelope containing a liquid,  such as n-
pentane converting to a gas at body temperature. The device can expand to a size larger 
than the pyloric canal for retention in the stomach. Instead of low - boiling point organic 
solvents,  osmotic  agents  can  be  used  to  inflate  the  envelope.  This  approach,  while 
effective, is not easy to implement.
28
Highly Swelling Hydrogel Dosages Forms
Hydro gels can be retained in the stomach by swelling to size larger of the pyloric 
canal. Although a hydro gel can swell to hundreds of times its dried size, it swelling is 
very slow. Its takes several hours before it reaches a size large enough to be retained in 
the stomach. Because the cyclic IMMC movement occurs every 2 hours, the hydro gel is 
most likely to be expelled from the stomach before it swells to required size. Thus hydro 
gels should posses a fast swelling property to be useful as a gastric retention device.
Co-Administration of Gastric-Emptying Delaying Drugs
This concept of simultaneous administration of a drug to delay gastric emptying 
together with a therapeutic drug has not received the favour of clinicians and regulatory 
agencies because of the questionable benefit-to-risk ratio associated with these devices.
Advantages of Prolonged Gastric Retention on Dosage Forms
1.  Prolonging  the  gastric  retention  of  dosage  forms  provide  therapeutic 
benefits such as local treatment and enhanced bioavailability.
2. Reduce drug wastages.
3. One group of drugs that would benefit form retentive formulations is those 
are  absorbed in  a  relatively  narrow region in  the  proximal  part  of  the 
gastrointestinal tract.
4. Drugs that  are  less  soluble  in  the  higher  pH environment  of  the small 
intestine than in the stomach may also benefit from gastric retention.
5. Another application of gastric retentive devices is for local delivery to the 
stomach and proximal, small intestine.
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Advantages of Floating Dosage Forms
1. Floating  dosage  forms  offers  various  future  potential  as  evident  form 
several recent publications. The reduced fluctuations in the plasma level of 
drug results from delayed gastric emptying.
2. Drugs that have poor bioavailability because of their limited absorption to 
the upper gastro intestinal tract absorption and improving their absolute 
bioavailability.
3. Buoyant  delivery  system  considered  as  a  beneficial  strategy  for  the 
treatment of gastric and duodenal cancers.
4. The floating concept can also be utilized in development of various anti-
reflux formulations.
5. Developing the control release system for drugs, which are potential  to 
treat Parkinson's diseases.
6. To explore  the  eradication  of  Helicobacter  pylori  by using  the  narrow 
spectrum antibiotic
Limitations of Floating Drug Delivery System
1. The  major  disadvantage  of  floating  systems  is  requirement  of  a 
sufficiently high level of fluid in the stomach for the drug. However this 
limitation can be overcome by coating the dosage form with the help of 
bioadhesive  polymers  that  easily  adhere  to  the  mucosal  lining  of  the 
stomach.
2. The dosage form should be administered with a minimum of glass full of 
water (200 - 250 ml)
3. Floating system is  not feasible  for those drugs that  have solubility or 
stability problems in gastric fluids.
4. Some drugs  present  in  the  floating  system causes  irritation  to  gastric 
mucosa.
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Table No.5 Patents of Some Floating Delivery Systems 4
S. No US Patent Number Patent Title
1. 6,207,197 Gastroretentive controlled-released microspheres 
for improved drug delivery
2. 5,972,389 Gastricretentive, oral drug dosage form for the 
controlled release of sparingly soluble drugs and 
insoluble matter
3. 5,443,843 Gastric retention system for controlled drug release
 
4. 5,232,704 Sustained-release,bilayer buoyant dosage form
5. 5,169,638 Buoyant controlled release powder formulation
6. 4,814,179 Floating sustained –release therapeutic 
compositions
7. 4,767,627 Drug delivery device that can be retained in the 
stomach for a controlled period of time
8. 4,167,558 Novel sustained – release formulation
9. 4,140,755 Sustained – release tablet  formulation
10. 4,126,672 Sustained – release pharmaceutical capsules
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1.4 Tablets 5
Among all the oral administered forms of dug the tablet are most conventional 
both from the point of view of the patient as well as the manufacturer. The tablets are the 
unit dosage forms these    are mainly spherical in shape but the shape can be round, oval, 
oblong etc., these are manufactured by the compression and compaction of the granules 
and other additives. Tablets have the following advantages along with all advantages of 
solid dosage form.
Advantages of Tablets:
1. Ease of handling: The tablet unique the liquid they do not require more space for 
storage.
2. Transportation:  The drug when present in the Tablet  can be easily transported 
from one place to another.
3. Less  prone to  Microbial  Infections:  These drugs  have a  definite  dose and the 
accuracy is maintained. This dose accuracy is not maintained in liquid dosage 
form.
4. Tamper  proof:  Tablet  can  not  be  easily  tampered  or  they  are  less  prone  to 
adulteration as compared to their liquid dosage forms.
5. Ease of Manufacturing: Manufacturing of Tablet is  not as complicated and costly 
as the 
6. Liquid dosage form.
7. Their cost is lowest of all the oral dosage forms.
8. They are the lightest ad most compact of all the dosage forms.
9. They are in  general  the easiest  and cheapest  to  package and ship of  all  other 
dosage forms.
10. Product identification is simplest and cheapest when employing an embossed or 
monogrammed punch.
11. They provide the case of swallowing with least  tending to hang up especially 
above the stomach.
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12. They lend themselves o certain special release profile such as enteric coated or 
delayed release products.
13. They are later suited to large scale productions the other unit oral forms.
14. Greatest dose precision and the least content variability.
Disadvantages
1. Some drugs resist  compression  into dense compact  owing to their  amorphous 
nature or flocculent, low density character.
2. Drugs with poor wetting, and slow dissolution properties, intermediate to large 
dosages, optimum absorption high in the gastrointestinal tract or any combination 
of these features may be difficult or impossible to formulate and manufacture as a 
tablet that will still associate adequate or full dug bioavailability.
3. Bitter tasting drug with an objectionable odor or that are sensitive to oxygen or 
atmospheric moisture may require encapsulation or entrapment.
4. They do no give  maximum bioavailability  in  the  same duration  in  which  the 
liquids achieve maximum plasma levels.
Properties of Tablets
1. Tablets  should be an elegant  product having own identity which being free of 
defect. Such as chips, cracks, discoloration, contaminant etc.,
2. Should  have  the  strength  to  withstand  the  rigors  of  mechanical  shocks 
encountered in its production, packaging, shipping etc.,
3. Should have the chemical and physical stability to maintain its physical attribute 
over times.
4. It should be able to release the medicinal agent in predictable and reproducible 
manner.
5. Must have a suitable chemical stability over time so as not to allow alteration of 
the medicinal agents.
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Types and Class of Tablets
The tablets an be classified by their
1. Route of administration or functions.
2. By the type of drug delivery system they represent within that route.
3. By the form and method of manufacture.
 Tablets ingested orally:
• Compressed Tablets or Standard Compressed Tablets
• Multiple Compressed Tablets
• Sugar Coated Tablets
• Film Coated Tablets
• Gelatin Coated Tablets
• Enteric Coated Tablets   
• Buccal or Sublingual Tablets   
• Lozenges or Troches
• Chewable Tablets
• Effervescent Tablets
• Molded Tablets
• Tablet Triturates
• Hypodermic Tablets
• Immediate Release Tablets
• Vaginal Tablets
• Modified Release Tablets  
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Floating Tablets
 
Floating systems: These systems are retained in the stomach and are useful for 
drugs that are poorly soluble or unstable in intestinal fluids. The underlying principle is 
very simple. One attempts to make the dosage form less dense than the gastric fluids so 
that it can float on them. The density of the system can be reduced by incorporating a 
number of low density fillers  into the systems such as hydroxyl  cellulose,  lactates  or 
microcrystalline cellulose. However, this system is not ideal because its performance is 
highly dependent on the presence of food and fluid in the stomach. It is not reliable and is 
highly variable. The basic idea behind the development of such a system was to maintain 
a constant level of drug in the blood plasma inspire of the fact that the drug dose not 
underage disintegration. The drug usually keeps floating in the gastric fluid and slowly 
dissolves at a predetermined rate to release the drug from the dosage form and maintain 
constant drug levels in the blood. The concept of floating tablets is mainly based on the 
matrix type drug delivery system such that the drug remains embedded in the matrix 
which after coming in contact with the gastric fluid swells up and the slow erosion of the 
drug without disintegration of the tablet takes place. Sometimes for generating a floating 
system we even need to add some effervescent or gas generating agent which will also 
ultimately reduce the density of the system and serve the goal of achieving a floating 
system for onward drug delivery.
These systems have particular advantage that they can be retained in the stomach 
and assist  in  improving  the  oral  sustained  delivery  of  drugs  that  have  an  absorption 
window in  a  particular  region  of  the  G.I.  tract.  There  systems  help  in  continuously 
releasing  the  drug  before  it  reaches  the  absorption  window,  thus  ensuring  optimal 
bioavailability.   
Several approaches are currently used to prolong the gastric retention time. These 
include  floating  drug  delivery  systems  also  known  as  hydro  dynamically  balanced 
systems, polymeric bio-adhesives systems, modified shape systems, high density systems 
and other delayed gastric emptying devices, The principle of buoyant preparation offers a 
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simple and practical approach to achieve increased gastric gastric residence time for the 
dosage form and sustained drug release.
Formulation of Floating Tablets
Non-effervescent  System
Commonly used excipients,  here are gel-forming or highly swellable  cellulose 
type hydrocolloids, polysaccharides and matrix forming polymers such as polycarbonate, 
polyacrylate, polymethacrylate and polystyrene. One of the approaches to the formulation 
of  such  floating  dosage  forms  involves  intimate  mixing  of  drug  with  a  gel  forming 
hydrocolloid,  which  swells  in  contact  with  gastric  fluid  after  oral  administration  and 
maintains a relative integrity of shape and a bulk density of less than unity within the 
outer gelatinous barrier.
The  air  entrapped  by the  swollen  polymer  confers  buoyancy  to  these  dosage 
forms. The gel structure acts as a reservoir for sustained drug release since the drug is  
slowly released by a controlled diffusion through the gelatinous barrier.
Effervescent System
This  Buoyant  Delivery  System  is  prepared  with  swellable  polymers  such  as 
methocel  or  polysaccharide  e.g.chitiosan  and  effervescent  component  e.g.  sodium 
carbonate e.g. sodium bicarbonate, citric or tartaric acid or matrices containing chamber 
of liquid that gasify at body temperature. The matrices are fabricated so that upon contact 
with gastric fluid, carbon dioxide is liberated by the acidity of gastric contents and is 
entrapped in the gelyfied hydrocolloid. This produces upward motion of the dosage form 
and  maintains  its  buoyancy.  The  carbon  dioxides  generating  components  may  be 
intimately  mixed  within  the  tablet  matrix  to  produce  a  single-layered  tablet  or  a  bi-
layered tablet may be compressed which contains the gas generating mechanism in one 
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hydrocolloid containing layer and the drug in the other layer formulate for the sustained 
release effect. The floating dosage forms are kept in the stomach for extended periods of 
time the therapeutics agents not immediately released after ingestion. Controlled release 
of such therapeutic  agents from the dosage forms prevents enzyme saturation thereby 
improving the biovailability of such therapeutics agents. So it improves the biovailability 
of by administering such therapeutic agent in a floating dosage form. 
Excipients for Floating Tablets
1. Hydrophilic Polymers: Hydroxy propyl methyl cellulose (Metolose)
2. Gel  forming  hydrocolloids  Matrix  Formers:  Polyacrylate, 
Polymethacrylate, Polycarbonate, Polystyrene
3. Swellable polymers used in Effervescent Systems: Chitosan and Sodium 
bicarbonate and Citric acid or Tartaric acid
4. Matrix  forming  polymers:  HPMC,  Polysaccharides,  Carageenan  gum, 
Gum Arabic
5. Fillers: Lactose, Microcrystalline cellulose
6. Lubricants: Magnesium stearate, Purified talc
7. Buoyancy agents: Hydrocolloids, Sodium bicarbonate and Citric acid or 
Tartaric acid
8. Porosity Agents: Lactose
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1.5 Asthma Management 6
Asthma remains one of the most common diseases, affecting an estimated four to 
five percent of the population.  It perhaps the only common treatable condition that is 
increasing in terms of prevalence, severity and mortality. Intensive research over the fast 
decades has significantly enhanced our understanding of the pathophysiology of asthma. 
This has also expanded the scope for new therapies; consequently the management of 
asthma has undergone a remarkable  transformation resulting in  more effective  use of 
existing therapies.
The introduction of inhaled beta 2 adrenergic agonist, which remains the most 
useful bronchodilators, has been an important landmark in asthma therapy. However the 
development of inhaled anti-inflammatory therapy (corticosteroids) has an even greater 
impact. The drugs act on the all-important inflammatory component the root cause of 
asthma.
Figure No.7 (a) Asthma prevalence world wide
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Cross-section of Asthmatic airwaysCross-section of Normal airways  
Figure No.7 (b) Asthma prevalence world wide
Asthma
Definition
Asthma  is  a  reversible  obstructive  airway  disease  (ROAD)  characterized  by 
bronchial hyperactivity (BHR).
Mechanism of Bronchial Obstruction in Asthma
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Early Asthmatic Response (EAR) ( Due 
to mast cell mediator release)
Late Asthmatic Responses Due to T-
cell mediated influx of inflammatory 
cells, chiefly esinophils
Bronchial hyper responsiveness (inflammation 
treated with anti- inflammatory drugs)
Treated with anti-inflammatory drugs.
Reversible Obstruction of Airways 
disease (ROAD) (Bronchopasam)
Treated with bronchodilators.
Asthma  is  related  to  atopy.  Atopy  is  a  familial  tendency  to  develop 
hypersensitivity  after  exposure  to  allergens.  It  is  an  autosmal  dominant  trait.  Atopic 
individual frequently suffer from allergic Rhinitis, bronchial asthma, atopic dermatitis, 
eczema or urticaria.  These disorders, mediated by immunoglobulin E (Ig E). Atopic do 
not develop the disease. What causes atopic individual to develop is not exactly known.
Development of Asthma
Atopic individual are to sensitized after an exposure to allergens   and develops Ig 
E antibodies,  subsequently exposure to an allergens  causes a dual  response,  which is 
protracted and more severe.
Components of Asthma
1. ROAD (Bronchopasam), which can be reversed with bronchodilators.
2. BHR due to inflammation (which predisposes patients to recurrent bronchospasm 
with minor triggers like exercise, smoke, dust exposure  etc.,). This is treated best 
with anti-inflammatory drugs such as corticosteroids.
Mechanism of Asthma Development
Allergic exposure
                       
40
Triggers
1. Allergic
a) Allergen
Inhaled eg. Dust, pollen, house dust mice (carpets, drapes and soft toys). Animal 
dender (pets) fungi, molds and spores, cockroaches.
b) Additives in foods
Tartrazine yellow dye as a colouring agent.
            Met bisulphate preservative used in beers, wines and preserved foods.
c) Occupational allergens e.g. Grain dust, wood dust.
II. Non Allergic
a) Infection, mainly viral.
b) Exercise.
c) Emotions e.g. Extreme joy, sorrow
d) Change in environmental temperature, humidity, gra
Other causative agents
1. Gastro-oesophageal reflux disease (GERD).
2. Rhinits, Sinusitis, post-nasal drip.
3. Aspirin/NSAID sensitivity.
4. Beta-blockers
5. Discontinuation or irregular use of preventive therapy.
Management of Asthma
1. Allergen avoidance
2. Pharmacotherapy
3. Immunotherapy
Allergen Avoidance
 Prevention consists of avoidance of allergens and provoking factors.  A detailed 
and appropriated history should help in identifying the Dust free atmosphere in the house 
or  work  place.  Keeping  minimum  furniture,  avoiding  carpets  using  wet  mopping  or 
vaccum can do this. Cleaning and making use of mattresses or pillows.
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Immunotherapy
Immunotherapy by use of allergen injection was introduced in the early 20 th 
century.  In  North  America,  it  was  the  treatment  of  choice  for  allergic  Rhinitis  and 
Asthma.  In  United  Kingdom,  however  it  was  never  widely  use,  perhaps  due  to 
availability of selective beta -agonist and inhaled steroids 15 year before they would be 
prescribed  in  US.  Recent  recommendations  do  not  advise  allergen-injection 
immunotherapy for asthma due to the uncertain efficacy multiplicity to the allergens and 
potential for serious side effect.
Pharmacotherapy
The  pharmacotherapy  of  asthma  consists  of  two  basic  classes  of  medication, 
quick-relief and long-term preventive medication.
1. Quick- relief medications
Otherwise  called  Relievers,  bronchodilators  that  gives  immediate  relief  of 
symptoms, but their affect does not last for none than 4 to 6 hours eg. Salbutamol
 2.  Preventer (Long term preventive medication)
Will not give immediate relief, but when given over prolonged periods of time 
will control the asthma better and prevent further attack. The anti-inflammatory 
glucocorticosteroids are most important in this class of medication. 
Asthma  management  today  focuses  on  the  judicious  and  adequate  usage  of 
preventive medication so that minimal or nil usage of quick-relief medication is required.
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TableNo.6 Class of Drugs Used For Management of Asthma
S.No Relievers Preventers
1. Short acting beta 2 agonist
E.g.
Salbutamol, 
Terbutaline,
 Levo-Salbutamol
Corticosteroids
E.g. 
Oral
 Prednisolone, 
Betamethasone,
Inhaled
Fluticasone, Budesonide, 
Beclomethasone
2. Anti-cholinergic
Iprtropium bromide, 
Long acting beta 2 agonist
Inhaled
Salbutamol, Formeterol
Oral
Sustained release dosage 
form Salbutamol, 
Terbutaline,Bambuterol
3. Short acting Theophylline Combination 
therapy
Fluticasone and Salmeterol
Budesonide and Formeterol
4. Adrenaline injection Leukoterine 
modifier 
Montilukast
Zafirlukast
5. - Mast cell stabilizer
Sodium chromo glycolate
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2. Literature Review
V.  F.  Patel  et.  al., 7  (2007) Statistical  evaluation  of  influence  of  viscosity  of 
polymer  and type  of filler  on Dipyridamole  release  from floating matrix  tablets.  The 
study investigates the influence of viscosity of HPMC and types of filler on dipyridamole 
release from floating matrix tablets. 
Dave B.S,  Amin  AF et.  al.,8  (2007)  Gastro  retentive  drug delivery  system of 
ranitidine  hydrochloride  formulation  and  invitro  evaluation,  the  floating  tablet  were 
formulated  by  using  guar-gum,  xanthangum,  HPMC,  by gas  forming  agent  and also 
studied the effect of stearic acid and citric acid on the drug release profile and floating 
profile was investigated. The addition of stearic acid reduces the drug dissolution due to 
its hydrophobic nature, the result showed that low amount of citric acid and high amount 
of  stearic  acid  favor  sustained  release  of  ranitidine  hydrochloride  from  the  gastro-
retentive formulation.
V.F  Patel  et.al.,9  (2005)  Studies  on  formulation  and  evaluation  of  ranitidine 
floating  tablets.  Present  investigation  highlights  the  formulation  and optimizations  of 
floating tablets of ranitidine hydrochloride, formulation were optimized for type of filler, 
polymer was used. Study revealed the type of filler had significant effect on the release of 
drug from the hydrophilic matrix tablets and floating properties.
J.Goole et.al., 10 (2007) Development and evaluation of new multiple-unit Levo-
dopa  sustained-release  floating  dosage  forms  by  melt  granulation.  The  investigation 
shows mini tablet composition and mini tablet diameter had the grate influence on the 
drug release. This was sustained for more than 8 hours.
Xu Xiaogiang et.al., 11 (2006) Floating matrix dosage form for Phenorporlamine 
Hcl  based  on Gas-forming  agent.  The study has  investigated  the  release  of  a  highly 
aqueous soluble drug, Phonorporlamine form a gastric retention based on floating matrix 
tablets.
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Garg S. Sharma.S et.al., 12 (2003) Gastro retentive drug delivery systems, the size 
and shape of the dosage unit also affect the gastric emptying. The tetrahedron and ring 
shape device have better gastric residence time as compared with the other shape.
Nur Ao, Zhang J.S et.al., 13  (2000) Captopril floating and or bio adhesive tablet, 
design an release kinetics. Developed floating tablets of captopril using HPMC (4000, 
5000 cps) and carbopol 934 invitro buoyancy studies revealed that   tablet of 2 kg/cm2 
hardness after immersion into the floating media floated immediately and the tablets with 
hardness 4 kg/cm2 sank for 3 to 4 minutes and then came to the surface.  Tablet in both 
cases  remained  floating  for  24  hours.  The  tablet  with  8-kg/cm2 hardness  shows  no 
floating capability. It was concluded that the buoyancy of the tablet is governed by both 
the swelling of the hydrocolloids particles on the tablet surface when it contact the gastric 
fluids and presence of internal voids in the center of the tablet. a prolonged release from 
these floating  tablet  was observed as  compared  with  the  conventional  tablets  and 24 
hours controlled release from the dosage from  of captopil was achieved.   
EI-Glibaly  I  et  al., 14  (2002) Prepared  and  evaluated  floating  chitosan 
microcapsules  for  oral  use  by  comparing  with  non-floating  chitosan  microcapsules. 
Floating microcapsules containing melationi  were prepared by the ionic interaction of 
chitosan and a negatively charged surfactant, sodium diethyl sulfosuccinate and evaluated 
for its drug release and floating tendency by comparing with non floating microcapsules.
Rouge  N  et  al.,15  (1998) Studied  the  pharmacokinetic  parameters  of  floating 
multiple- unit capsule, a high-density multiple-unit capsule and immediate –release tablet 
containing  25 m atenolol.  Atenolol  was chosen as  a  model  drug because  of  its  poor 
absorption  in  the  lower  gastrointestinal  tract.  The  bioavailability  of  the  two-
gasroretentive  preparations  with  sustained  release  characteristics  was  significantly 
decreased when compared to the immediate-release tablet. This study concluded that it 
was not possible to increase the bioavailability of a poorly absorbed drug such as atenolol 
using gastro retentive formulations.
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Manuel Efentakis et al., 16 (2000) Developed and Evaluated Oral Multiple-unit and 
Single-unit  Hydrophilic  Controlled-release  Systems  using  furosemide  as  model  drug. 
This study compared the release behavior of single-unit release systems of furosemide by 
using two hydrophilic swellable polymers sodium alginate (high viscosity) and carbopol 
974 p. Swelling and erosion experiments showed a high degree of swelling and limited 
erosion  or  the  carbopol  preparation,  Whereas  less  swelling  but  greater  erosion  was 
observed for the sodium alginate  preparations.  It  is  concluded that  all  three carbopol 
dosage forms (single and multiple-unit) displayed similar release behavior while sodium 
alginate dosage forms displayed a different and more distinctive behavior. This shows 
polymer characteristics influence the drug release.
A.Streubel et al.,  17  (2003) Developed a new preparation method for low density 
foam-based,  floating  micro  particles  and  to  demonstrate  the  systems’  performance 
invitro. The prepared floating micro particle consisting of polypropylene foam powder, 
model drug chlorpheniramine maelate, diltiazem Hcl, theopylline or verapamil Hcl and 
polymer (Eudragit RS or polymethyl methacrylate (PMMA) by soaking the micro porous 
foam carrier with a organic  solution of drug and polymer and subsequent drying. And 
they studied the effects of various formulation and processing parameters on the resulting 
in vitro floating behavior, internal and external particle morphology, drug loading, invitro 
drug release  and physical  state  of  the  incorporated  dug.  They concluded  that  all  the 
formulation  shows good floating  behavior  as  well  as  shows a  broad variety  of  drug 
release pattern.
Umamaheswari  RB et al., 18  (2003) studied a new approach in gastro retentive 
drug  delivery  system  using  cholestyramine.  They  prepared  cellulose  acetate  butyrate 
coated cholestyramine  microcapsules  endowed with floating ability  due to the carbon 
dioxide generation when exposed to the gastric fluid. These microcapsules also have a 
mucoadhesive property. And loaded particle in ion exchange resin. The studied the effect 
of cellulose acetate butyrate: drug resin ration (2:1, 4:1, 6:1 w/w) on the particle size, 
floating  time  and drug release.  And it  was  concluded  that  the  buoyancy time  of  the 
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cellulose  acetate  butyrate-coated  particles  and it  shows good mucoadhesive  property. 
They suggest that cellulose acetate butyrate micro particles could be a floating as well as 
a mucoadhesive drug delivery systems.
Inouye K et al., 19  (1988) Prepared and studied buoyant sustained release tablets 
based on chitosan. Two kinds of chitosan with different degrees of deaetylation Chitosan 
H and L) were used, and two types of preparations (type A and B) were examined using 
prednisolone  as  model  drug.  Type  A  is  direct  compressible  tablets  using  sodium 
bicarbonate  and  citric  acid  and  Type  B  is  direct  compressible  layer  of  chitosan  H 
enclosing sodium bicarbonate. The study concluded that Type B preparation gives quick 
buoyancy  and  a  good  sustained  release  of  drug  when  compared  to  the  Type  A 
preparation.
Sato  Y et  al., 20 (2003) Performed  in  vivo  evaluation  of  riboflavin-containing 
micro balloons for floating controlled drug delivery system in healthy human volunteers. 
Microballons  were  prepared  by  emulsion  solvent  diffusion  method  utilizing  enteric 
acrylic  polymer  dissolved  in  a  mixture  of  dichloromethane  and  ethanol.  Riboflavin 
powder, riboflavin-containing microballons, and riboflavin-containing non-floating micro 
spheres  wee  administered  orally  to  each  of  three  healthy  volunteers.  Riboflavin 
pahrmacokinetics was investigated via analysis of urinary excretion of riboflavin. It was 
concluded that riboflavin containing microballons shows good floating property and a 
efficient sustained release compared to the other preparations.
John T. Fell et.al., 21 (2000) Prepared and evaluated amoxycillin release from  a 
floating dosage form based on alginates. The study has investigated the release of soluble 
drug, amoxyicillin tri hydrate from a gastric retentive system based on alginates.
Shoufeng Li et al., 22 (2001) Studied the statistical optimization of gastric floating 
system  for  Oral  Controlled  Delivery  of  calcium  properties,  Optimization  of  the 
formulation was calcium, a very important building mineral for our bones, is absorbed 
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primarily in the duodenum as a result of the presence of active absorption sites (calcium 
binding protein) in the upper GI tract. The development of an optimized gastric floating 
drug delivery system us described by statistical  experimental design and data analysis 
using response surface   methodology. A central, composite Box-Wilson design for the 
controlled release of calcium was use with formulation variables Hydroxyl propyl methyl 
cellulose  loading,  Citric  acid  loading,  and  Magnesium  stearate  loading.  Dissolution 
studies and floating kinetics wee performed on these formulation and data are fitted to 
power  law.  It  was  concluded  that  all  three-formulation  variable  were  found  to  be 
significant for the release properties (p<0.05), while only HPMC loading was found to be 
significant for floating properties.
Sunil  K.Jain  et  al., 23  (2005) Prepared  calcium  silicate  based  microspheres  of 
repaglinide as gastro retentive floating drug delivery and carried out invitro evaluation, 
The calcium silicate microsphere are prepared by emulsion solvent diffusion technique 
consisting of calcium silicste as porous carrier, repaglinide , an oral hypoglycemic agent 
and Eudragit S as polymer. Various parameters where evaluated and physical stare of the 
incorporated drug was studied. Encapsulation efficiencies close to 100% was achieved by 
varying either the ratio amount of ingredients volume of the organic phase or the relative 
amount of polymer. In all cases, good invitro floating behavior was observed. The release 
rate increased with increasing drug loading and with decreasing polymer amounts. The 
type  of  polymer  significantly  affected  the  drug  release  rate,  which  increased  in  the 
following rank order: PMMA<EC<Eudragit RS.
Choi B.Y. et al., 24 (2002) Prepared alginate beads as floating drug delivery system 
and studied the effect of CO2     gas forming agents. Floating beads were prepared from a 
sodium  alginate  solution  containing  CaCO3 or  NaHCO3  as  gas  forming  agents.  The 
effects of gas forming agents on bead size and floating properties were investigated. The 
study concluded that CaCO3 in superior to NaHCO3  as a gas forming agent in alginate 
bead preparations. The enhanced buoyancy and sustained release properties of CaCO3 - 
containing  beads make them an excellent  candidate  for floating  drug dosage systems 
(FDDS).
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EI-Kamel A.H.et al,. 25  (2001) Prepared and evaluated ketoprofen floating oral 
delivery system. Floating micro particles were prepared by emulsion-solvent diffusion 
technique. Four different ratios of Eudragit S100 (ES) with Eudragit RL (ERL) were used 
to form the floating micro particles. All floating micro particle formulations showed good 
flow properties and packability. It is concluded that release rate were generally low in 0.1 
N HCL  especially in presence of high content of ES while in phosphate buffer pH 6.8, 
high  amount  of  ES tended to  give  a  higher  release  rate.  The formulation  containing 
ES:ERL  exhibiting high percentage of floating particles in all examined media.
Y.Murata et al., 26 (2000) Prepared floating alginate beads using metronidazole as 
model drugs. Two types of alginate beads containing vegetable oil and chitosan were 
prepared  and  drug  is  loaded.  The  preparation  are  compared  and  evaluated.  The 
concentration of drug at the gastric mucosa after administration of chitosan beads was 
higher  than  that  in  the  solution,  though  the  drug  serum concentration  was  the  same 
regardless  of  which  type  of  gel  was  administered.  It  is  concluded  that  the  release 
properties of alginate gels are applicable not only for sustained release of drugs but also 
for targeting the gastric mucosa.
A.K. Hilton et al., 27 (1992) Studied in- vitro and in-vivo evaluation of an oral 
sustained-release dosage form of Amoxicillin Trihydrate. Various hydrophilic polymers 
were investigated for the preparation of amoxicillin trihydrate sustained-release tablets. 
The study concluded that further formulation to enhance gastric retention time (GRT), by 
incorporation of gas-generating  system,  yielded either  bilayer  tablets  that prematurely 
failed or large single –layer which remained buoyant for 6 hours and had satisfactory 
invitro sustained release of the drug.
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S.Sangekar et al.,  28(1987) Evaluated the effect of food and specific gravity of 
tablets on gastric retention time. In this study the effect of food and specific gravity on 
the gastric retention time of floating (spec. grav. 0.96) and non-floating (spec. grav. 1.59) 
tablet  formulation  was  investigated  using  gamma  scitigrapy  in  humans.  The  results 
obtained  indicate  that  the  presence  of  food  in  the  stomach  appears  to  significantly 
prolong  gastric  retention  of  both  the  floating  and  non-floating  tablets  while  specific 
gravity does not seem t play and important role in the residency time of the tablets in the 
stomach.
Pronsak Sriamornsak et al., 29 (2004) Studied the morphology and buoyancy of oil-
entrapped calcium pectinate gel beads. Anew emulsion-gelation method to prepare oil-
entrapped calcium pectinate gel beads capable of floating in the gastric condition was 
designed  and  tested.  The  type  and  percentage  of  oil-entrapped  CaPG  beads  were 
promising as a carrier for intragastric floating drug delivery.
Talukder R et al., 30 (2000) Studied on various attempts to develop gastro retentive 
delivery systems through floating, swelling, mucoadhesive, and high-density systems to 
increase gastric retention time of the dosage forms was studied and the differences in 
gastric physiology, gastric pH and gastric motility in both intra as well as inter subject 
variability, significant impacts on gastric retention time and drug delivery behavior was 
found to be investigated.
Streubel A et al., 31 (2000) Prepared and evaluated of floating microparticles based 
on low-density foam powder was studied. The study developed a novel multiparticulate 
gastro  retentive  drug  delivery  system  and  to  demonstrate  its  performance  in  vitro. 
Floating  microparticles  consisting  of  polypropylene  foam  powder,  verapamil  Hcl  as 
model  drug, Eudragit  RS, ethyl  cellulose or polymethamethacrylate  as polymers were 
prepared  with  an  O/W  solvent  evaporation  method.  The  various  formulations  and 
processing parameters on the internal and external particle morphology, drug loading, in 
vitro floating, in vitro drug release kinetics, particle size distribution and physical state if 
the incorporated drug was studied.
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Arora J et al., 32  (2004) Studied the development and evaluation of floating drug 
delivery system for cefecoxcib using hydrocolloids to increase the gastric residence time 
of the celecoxcib in gastro intestinal tract and Eudragit RS 100, REO WSR 60 K were 
found to have good buoyancy , and it is suitable for floating drug delivery.
Archana et  al., 33  (2004) Studied celecoxib  multi-unit  controlled  release  gastro 
retentive  drug  delivery  systems.  It  was  prepared  by  microencapsulation  of  drug  and 
swellable  polymer  along  with  gas  generating  agent  for  prolonged  residence  in  the 
stomach and controlled release of the drug.
Muthusamy K et al., 34 (2005) Prepared and evaluated for lansaprozole floating 
micro pellets by emulsion solvent diffusion technique. Floating micro pellets of 1:1,1:2 
and  1:3  drug  to  carrier  ratios  were  prepared  using  hydroxypropylmethylcellulose, 
methylcellulose, and chitosan as a carrier. Stability studies, scanning electron microscopy 
and particle size analysis, particle size distribution, and were studied.
Basak S.C. et al., 35 (2004) Studied the development and in vitro evaluation of an 
oral floating matrix  tablet  formulation of ciprofloxacin.  In vitro drug release study of 
tablets indicated that gas powered floating matrix tablet could be promising delivery sys 
tem for ciprofloxacin with sustained release action and improved drug availability.
Julijana kristl et al., 36  (2000) Studied the optimization of floating matrix tablets 
and evaluation of their gastric residence time. Crushing force, floating properties, in vitro 
drug release properties was examined.
Masaki Ichikawa et al., 37  (199) Studied a new multiple unit oral floating dosage 
system.  Multiple  unit  oral  floating dosage system.  Multiple  unit  type  of oral  floating 
dosage system has been prepared in oral  to prolong the gastric  emptying time of the 
preparation. The floating ability and the sustained release character of the system have 
been evaluated by invitro dissolution method.
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Kawashima Y. et al., 38 (1992) Studied a hallow miocrospheres floating controlled 
drug delivery system loaded with drug in their outer polymer shells were prepared by a 
novel emulsion solvent diffusion method. The drug release behavior of the microballons 
was  characterized  as  an  enteric  property  and  the  drug  release  rate  were  drastically 
reduced depending on the polymer concentration
Fassiahi et al,. 39 (1996) The multi layered tablets was prepared and developed. An 
asymmetric three-layered table was found in that one of the outer layer consisted of a gas 
generating system with the produced carbon dioxide trapped in a hydrated gel matrix. 
The outer layer was similar but lacked the gas-generating element. The function of these 
layers was to provide the necessary buoyancy and to controlled the passage of fluids in to 
the central drug containing layer
.  Strebel et al., 40  (1997) Studied the multiple unit gastro retentive drug delivery 
system by a new preparation method for low-density micro particles were prepared and 
the invitro performance demonstrated.
Ingani  et  al.,  41  (1997) Studied  the  floating  drug  release  properties  of  a 
conventional  capsule  was  prepared  and  compared  with  a  tablet  containing  a  gas 
generating bilayer formulation.
Nadio passerine et al.,42 (2002) Studied the preparation and the characterization of 
carbamaxepine-gellucire 50/10 micro particulates by spray congealing method using ultra 
sounds  were  prepared.  The  SEM  analysis  showed  that  it  was  possible  to  obtain 
spherically shaped and non-aggregated micro particles. The particle size was in the range 
150-20 µm and the microsphees had good encapsulation efficiency.
Sato Y et al.,43  (2003) Studied the floating hallow microsphere was prepared by 
emulsion  solvent  diffusion  method  and  the  in  vitro  evaluation  and  drug  releasing 
behaviors were studied.
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U.S. patent44 No. 5,232,704 described bilayer, sustained release dosage form. One 
layer and other was a buoyant or floating layer. Each layer contained hydrocolloid gelling 
agent such as gums, polysaccharides, and hydroxypropyl methylcellulose. Patent claimed 
buoyancy of system in gastric fluid for a period up to 13hrs.
U.S. patent No.4, 418,179 described non-compressed sustained release floating 
therapeutic composition containing agar and light mineral oil. The light mineral oil used 
helps in preventing entrapped air from escaping when system is placed in gastric fluid 
and thus system attend buoyancy.
U.S.  patent  No.  WO  01/10405 described  hydro  dynamically  balanced 
multiparticulate  oral  drug  delivery  system  comprising  of  a  drug;  gas  generating 
components,  sugar,  release  controlling  agent  and a  spheronizing  agent.  As system is 
multiparticulate, incorporation of high dosage of drugs is a serious limitation.
U.S. patent No.5, 783,212 described a controlled release tablet having at least 3 
layers,  two  extreme  barrier  layers  containing  swellable  polymer(s),  gas  generating 
component and middle layer contained drug and release retarding polymer. 
U.S.  patent  No.WO  00/15198  (PCT)  and  WO  01/64183 described  a  very 
complicated  floating  drug  delivery  system  comprising  of  a  drug,  a  gas  generating 
component, a swelling agent, a viscolyzing agent and a gel forming polymer. This system 
used  higher  percentage  of  superdisintegrant  class  of  polymers  as  swelling  agent 
combination with viscolyzing agent /gel forming polymer entrapping gas, generated due 
to  gas  generated  component.  According  to  claims,  system  retained  in  upper  part  of 
gastrointestinal tract releasing drug in controlled rate. The system is complicated due to 
presence of so many controlling and floating ingredients. It is not cost effective in terms 
of manufacturing as well as packing is concerned, as it will require special packing to 
protect from moisture.
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List of Drug Formulated as Single and Multiple unit of FDDS45
S.No Approaches Model drugs References 
1. Floating Tablets Chlorpheniramine maleate Hirtz J  et.al., 
J.Clin.pharmacol 
1985(19), 77-87.
2. Floating Tablets Theophylline Yan L  et.al., 
J.pharm.Sci 
1996(85)170-173.
3. Floating Tablets Frusemide Yang L et.al., 
J.Control release 
1999(57)215-222
4. Floating Tablets Ciprofloxacin Talwa N et. al., 
US patent 6261601, 
July,17,2000
5. Floating Tablets Pentoxyfillin Baumgartner 
et.al.,
Int.J. pharm. 2000 
(195)125-135.
6. Floating Tablets Captopril Nur Ao  et.al.,
Drug Dev. Ind 
pharm 2000 
(26)2965-969.
7. Floating Tablets nimodipine Wu W  et.al., 
Yao Xue,Xue Bao 
1997 (32) 786-790.
8. Floating Tablets Amoxycillin trihydrate Hilton Ak  et.al., 
Int.J.Pharm Sci 
1992 (81)135-140.
9. Floating Tablets Verapamil Chen GL et.al., 
Drug Dev.Ind 
Pharm 1998 
(24)1067-1072.
10
.
Floating Tablets Isosobide di nitrate Ichikawa M  et al., 
J.Pharm Sci 1991 
(80) 1153-1150.
11
.
Floating Tablets Sotalol Cheuh HR et.al., 
Drug Dev.Ind 
Pharm 1995 
(21)1725-1747.
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12
.
Floating Tablets Atenolol Rouge N  et.al.,
PharmActa Helv. 
1998 (73) 81-87.
13
.
Floating Tablets Cinnarazine Machid Y et.al., 
Drug Des Deliv 
1989 (9) 155-161.
14
.
Floating Tablets Diltiazem Gu TH  et.al., (in 
Chinese) Chung 
Kao Yao Li Hsuesh 
Pao 1992 (13) 527-
531
15
.
Floating Tablets Florouracil Watanbe K et.al., 
Arch Pract Pharm 
Yakuzaigaku 1993 
(53)   1-7.
16
.
Floating Tablets Piretamide Rouge N  et. al. 
Pharm Dev Technol 
1998 (3) 73-84.
17
.
Floating Tablets Prednisolone Inouye K  et. al., 
Drug Des Deliv 
1988 (2) 165-175.
18
.
Floating Tablets Ribofluvin- 5’ phosphate Ingani  et.al., 
Int.J.Pharm 1987 
(35) 157-164.
19
.
Floating capsules Nicardipine Moursy NM  et.al.,
Pharmazie 2003 
(58) 38-43.
20
.
Floating capsules L-dopa and Benserazie Erni W  et.al., 
Eur Neurol 1987 
(27) 215-275.
21
.
Floating capsules Hlordiazepoxide Hcl Sheth PR  et.al.,
Drug De Ind Pharm 
1984 (10) 313-319.
22
.
Floating capsules Furosemide Menon A et.al.,
J.Pharm Sci, 1994 
(83) 239-245.
23
.
Floating capsules Diazepam Gustafson J.H  et. 
al.,
J.Pharmacokinet.Bi
opharm 1981 (9) 
679-691.
24
.
Floating capsules Propranolol Khattar D  et. al., 
1990 (45) 356-358.
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25
.
Floating 
microspheres
Verapamil Soppimath KS 
et.al., 
Drug Metab Rev 
2001 (33) 149-160.
26
.
Floating 
microspheres
Aspirin, Griseofluvin and 
p-nitro aniline
Thanoo BC et.al., 
J. Pharm.Pharmacol 
1993 (45) 21-24.
27
.
Floating 
microspheres
Ketoprofen El-Kamel AH 
et.al., 
Int. J.Pharm 2001 
(220) 13-21.
28
.
Floating 
microspheres
Tranilast Kawashima Y 
et.al., 
J. Control release 
1991 (16) 276-290.
29
.
Floating 
microspheres
Ibuprofen Kwawashima Y 
et.al., 
J.Pharma.Sci 1992 
(81) 135-140.
30
.
Floating Micro 
balloons 
Terfenadine Yayanthi G  et.al., 
Pharmazie 1995 
(50) 769 –770.
31
.
Floating Granules Indomethacin Hilton AK  et.al., 
Int.J.Pharm 1992 
(86) 79-88.
32
.
Floating Granules Diclofenac sodium Macolm SL  et.al., 
Eur Neurol 1987 
(27) 28S-35S.
33
.
Floating Granules Predinisolone Inouye K  et.al., 
Drug Des Deliv 
1989 (4) 55-67.
34
.
Floating Films Drug delivery device Harrigen BM 
US patent 4 055 
178 october 25 977.
35
.
Floating Powder Several basic drugs Dennis A 
Timminis P 
et.al., . US patent 5 
169 638 December 
8, 1992.
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    3. Aim and Objectives
Salbutamol sulphate  is  a  short  acting  bronchodilators  (β2 adrenergic  agonist), 
which have short biological half -life about 2.7 - 5 hours. It is available as conventional 
oral tablets, solution, inhalation (inhaler, nebulised solution).  The recommended dose of 
salbutamol in conventional dose 2 or 4 mg three or four times per day.
The aim of this project work is to develop the Salbutamol sulphate as Gastro 
Retentive Drug delivery System by Floating Matrix Tablets with extended drug 
release, for administration as once daily dose. Floating matrix tablets were formulated 
by different methods.
1. Non-effervescent method- by using Hydrocolloids
2. Effervescent method - by using Gas-forming agents
Thus, it is an object of the present invention to provide a Salbutamol as floating 
matrix tablets, which have gastro-retentive controlled oral drug delivery system. The 
objects include. 
To formulate a floating matrix tablet by using different matrix forming materials
1. Hydrophilic Floating Matrix Tablets 
Matrix forming material - Hydrocolloids like Methylcellulose, 
HPMC (K 100 M, K4M) etc.,
Approach                 - Non-effervescent method.
2. Insoluble Floating Matrix Tablets
Matrix forming material - Ethyl cellulose, and Eudragit RSPO
Approach     - Effervescent method.
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3. Combined  Floating Matrix Tablets
Matrix forming material - HPMC (K 100 M) hydrophilic polymer
Ethyl cellulose, Eudragit RSPO as hydrophobic 
polymer
Approach                 - Non-effervescent method.
Floating matrix tablets formulation
Wet granulation method non-aqueous solvents were used as granulating agents.
To control the release of the salbutamol sulphate from the Floating Matrix Tablets 
throughout 24 hours for administration as once daily dose. To achieve sustained release 
of  the  drug  from the  dosage  form by retaining  the  dosage  form in  the  stomach  for 
prolonged period (GRDDS) and controlled their drug release from the matrix tablet.
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4. Plan of Work
The Scheme of Proposed Work is as Follows:
Floating matrix tablets were formulated by using different matrix forming 
material and grouped as follows
1. Hydrophilic Floating Matrix Tablets 
2. Insoluble Floating Matrix Tablets
3. Combined Floating Matrix Tablets
Hydrophilic Floating Matrix Tablets
Formulation of Floating Matrix Tablets by Non- effervescent method.
Optimization  of  formula  for  formulation.  The  formula  was  optimized  by 
varying the following variables.
• Hardness 
• Polymer , Polymer concentration 25, 50, 75 % w/w
• Shape
• Effect of stearic acid on the drug release 
Insoluble Floating Matrix Tablets 
Optimization of Gas forming agent, and Polymer concentration.
Formulation of Insoluble Floating Matrix Tablets.
Combined Floating Matrix tablets 
Optimization of formula for formulation Floating Matrix Tablets
Formulation of Combined Floating Matrix Tablets.
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Preformlation Studies
1. Identification of drug by spectrophotometric method (UV, IR)
2. Bulk density
3. Carr's index
4. Angle of Repose
Evaluation 
1. Physical Evaluation
Weight variation
Hardness test
Friability test
2. Chemical Evaluation
            Drug content analysis
3. In vitro Drug Release
Drug dissolution profile in Simulated Artificial Gastric Fluid and 
Water
4. Floating properties
             Floating lag time
                   Duration of floating time
5. Stability studies
  As per ICH guidelines
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5. Drug and Excipient Profile
5.1   DRUG   PROFILE46
Drug Name - Salbutamol sulphate
Classification - β2  adrenergic agonist
Proper Name - The World Health Organization recommended 
name      
for Albuterol base is salbutamol.
Synonym - Albuterol sulphate
Chemical structure
                      H2SO4
Chemical Name - α1-[(tert-butylamino) methyl]-4-hydroxy-m-xylene- 
                         α,α'-diol sulfate
 Molecular weight  -  576.71
 Molecular formula -  (C13H21NO3)2   H2SO4
 Description
Colour - White to almost white powder
Odour - Odourless
Solubility - Soluble in four parts of water 
                 Slightly soluble in 96% ethanol
Melting point - 155ºC 
Optical rotation - Racemic mixture
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Mechanism of action47
Salbutamol
Stimulation of beta2 receptor
Present on bronchial smooth muscle
Activation of enzyme adenyl cyclase
Conversion of ATP into 3’5’ c AMP
Activation of enzyme protein kinase
Inhibiton of release of calcium ion into the cell 
Relaxation of smooth muscles (bronchodilation) 
Albuterol  is  a  moderately  selective  β2  -adrenergic  agonist  that  stimulates 
receptors of the smooth muscle in the lungs, uterus, and vasculature supplying skeletal 
muscle. Albuterol is racemic beta-agonist, comprised of an equal mixture of R- and S-
isomers.  The  R-isomer,  known  as  levalbuterol,  is  primarily  responsible  for 
bronchodilation. Although not confirmed during clinical trials, the S-isomer of albuterol 
has  bronchoconstrictive  properties  inanimalmodels.Intracellularly;  the  actions  of 
albuterol  are  mediated  by cyclic  AMP, the production of which is  augmented  by β2-
stimulation. Albuterol is believed to work by activating adenylate cyclase, the enzyme 
responsible for generating cyclic AMP, an intracellular mediator. Increased cyclic AMP 
leads  to  activation  of proteinkinase  A, which  inhibits  phosphorylation  of myosin  and 
lowers intracellular ionic calcium concentrations, resulting in relaxation. The net result of 
β2-receptor agonist in the lungs is relaxation of bronchial and tracheal smooth muscles, 
which  in  turn  relieves  bronchospasm,  reduces  airway  resistance,  facilitates  mucous 
drainage, and increases vital capacity.
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                  Albuterol can also inhibit the degranulation and subsequent release of  
inflammatory  autocoids  from  mast  cells.  Stimulation  of  β2-receptors  on  peripheral 
vascular smooth muscle can cause vasodilation and a modest decrease in diastolic blood 
pressure. Albuterol is an effective adjunctive treatment for hyperkalemia; β2-adrenergic 
stimulation results in intracellular accumulation of serum potassium due to stimulation of 
the Na/K ATPase pump, leading to moderate degrees of hypokalemia.
Pharmacokinetics47
             Albuterol can be administered as oral tablets or oral solution, but is more 
commonly  administered  by  oral  inhalation.  Following  oral  inhalation,  albuterol  is 
absorbed over several hours from the respiratory tract. It is postulated from studies with 
other inhaled bronchodilators that most of an albuterol inhaled dose (approximately 90%) 
is actually swallowed and absorbed through the GI tract. Onset of bronchodilation occurs 
within 5—15 minutes after oral inhalation, peaks in 0.5—2 hours, and lasts 2—6 hours. 
Administration  via  nebulization  does  not  appear  to  significantly  alter  the 
pharmacokinetics  of  albuterol.  When  administered  orally,  albuterol  is  well  absorbed 
through the GI tract. Onset of action begins within 30 minutes, peak levels are reached in 
2—3 hours, and duration of action is 4—6 hours for the conventional-release tablets and 
8—12 hours for the sustained release product.
             Albuterol crosses the blood-brain barrier and may cross the placenta. The liver 
metabolizes albuterol extensively to inactive compounds. Excretion of albuterol occurs 
through the urine and feces. After oral inhalation, 80—100% of a dose is excreted via the 
kidneys within 72 hours; up to 10% may be eliminated in feces. After oral administration, 
75% of a dose is excreted in urine within 72 hours as metabolites; 4% may be found in 
feces.  The  elimination  half-life  of  albuterol  ranges  from  2.7-5  hours,  with  orally 
administered albuterol having a shorter half-life than the inhaled product.
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Clinical Pharmacology
Absorption-Well absorbed from the GI tract
Metabolism-Considerable pre-systemic metabolism, the major metabolite 
is a sulphate conjugates
Elimination-Oral administration of salbutamol sulphate excretes via 
kidney 58% to 78%Of radiolabel appearing in the urine within 24 hours
Pharmacokinetic parameters
Oral absorption - 50%
Protein binding – 10%
Presystemic metabolism - Considerable 
Plasma half life - 2.7 to 5 hours
Volume of distribution - 3.4 ± 0.6l kg-
Maximum plasma concentrations        - 18 ng/mL 
Clinical Trials
      In controlled clinical trials in patients with asthma, the onset of improvement 
in pulmonary function, as measured by maximum midexpiratory flow rate (MMEF), was 
within 30 minutes after a dose of Albuterol tablets, with peak improvement occurring 
between  2  and  3  hours.  In  controlled  clinical  trials  in  which  measurements  were 
conducted for 6 hours, clinically significant improvement (defined as maintaining a 15% 
or more increase in forced expiratory volume in 1 second [FEV1] and a 20% or more 
increase in MMEF over baseline values) was observed in 60% of patients at 4 hours and 
in 40% at 6 hours. In other single-dose, controlled clinical trials, clinically significant 
improvement was observed in at least 40% of the patients at 8 hours. No decrease in the 
effectiveness  of  Albuterol  tablets  was  reported  in  patients  who  received  long-term 
treatment with the drug in uncontrolled studies for periods up to 6 months.
Indications and Usage for Albuterol
         Albuterol  tablets  are  indicated  for  the  relief  of  bronchospasm  in  adults  and 
children 6 years of age and older with reversible obstructive airway disease.
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Contraindications
      Albuterol tablets are contraindicated in patients with a history of hypersensitivity 
to Albuterol, or any of its components.
Warnings
Paradoxical Bronchospasm
          Albuterol tablets can produce paradoxical bronchospasm, which may be life  
threatening.  If  paradoxical  bronchospasm  occurs,  Albuterol  tablets  should  be 
discontinued immediately and alternative therapy instituted.
Cardiovascular Effects
            Albuterol tablets, like all other beta-adrenergic agonists, can produce a clinically 
significant  cardiovascular  effect  in  some  patients  as  measured  by  pulse  rate,  blood 
pressure, and/or symptoms. Although such effects are uncommon after administration of 
Albuterol  tablets  at  recommended  doses,  if  they  occur,  the  drug  may  need  to  be 
discontinued. In addition, beta-agonists have been reported to produce electrocardiogram 
(ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and 
ST  segment  depression.  The  clinical  significance  of  these  findings  is  unknown. 
Therefore,  Albuterol  tablets,  like  all  sympathomimetic  amines,  should  be  used  with 
caution  in  patients  with  cardiovascular  disorders,  especially  coronary  insufficiency, 
cardiac arrhythmias, and hypertension.
Immediate Hypersensitivity Reactions
           Immediate hypersensitivity reactions may occur after administration of Albuterol, 
as  demonstrated  by  rare  cases  of  urticaria,  angioedema,  rash,  bronchospasm,  and 
oropharyngeal  edema.  Albuterol,  like  other  beta-adrenergic  agonists,  can  produce  a 
significant  cardiovascular  effect  in  some  patients,  as  measured  by  pulse  rate,  blood 
pressure, symptoms, and/or electrocardiographic changes. Rarely,  erythema multiforme 
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and  Stevens-Johnson  syndrome  have  been  associated  with  the  administration  of  oral 
Albuterol sulfate in children.
Precautions
General
              Albuterol, as with all sympathomimetic amines, should be used with caution in 
patients  with  cardiovascular  disorders,  especially  coronary  insufficiency,  cardiac 
arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or 
diabetes  mellitus;  and  in  patients  who  are  unusually  responsive  to  sympathomimetic 
amines. Clinically significant changes in systolic and diastolic blood pressure have been 
seen in individual patients and could be expected to occur in some patients after use of 
any beta-adrenergic bronchodilator.
Large  doses  of  intravenous  Albuterol  have  been  reported  to  aggravate  preexisting 
diabetes mellitus and ketoacidosis. As with other beta-agonists, Albuterol may produce 
significant hypokalemia in some patients, possibly through intracellular shunting, which 
has  the  potential  to  produce  adverse  cardiovascular  effects.  The  decrease  is  usually 
transient, not requiring supplementation.
Information for Patients
          The action of Albuterol tablets may last up to 8 hours or longer. Albuterol tablets 
should not be taken more frequently than recommended.  Do not increase the dose or 
frequency  of  Albuterol  tablets  without  consulting  your  physician.  If  you  find  that 
treatment  with  Albuterol  tablets  becomes  less  effective  for  symptomatic  relief,  your 
symptoms get worse, and/or you need to take the product more frequently than usual, you 
should seek medical attention immediately. While you are taking Albuterol tablets, other 
asthma  medications  and  inhaled  drugs  should  be  taken  only  as  directed  by  your 
physician. Common adverse effects include palpitations, chest pain, rapid heart rate, and 
tremor or nervousness. If you are pregnant or nursing, contact your physician about use 
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of Albuterol tablets. Effective and safe use of Albuterol tablets includes an understanding 
of the way that it should be administered.
Drug Interactions
             The concomitant use of Albuterol tablets and other oral sympathomimetic agents  
is  not  recommended since such combined use may lead to  deleterious  cardiovascular 
effects.  This  recommendation  does  not  preclude  the  judicious  use  of  an  aerosol 
bronchodilator of the adrenergic stimulant type in patients receiving Albuterol tablets. 
Such concomitant  use,  however,  should be individualized  and not given on a routine 
basis.  If  regular  coadministration  is  required,  then  alternative  therapy  should  be 
considered.
Monamine Oxidase Inhibitors or Tricyclic Antidepressants 
            Albuterol should be administered with extreme caution to patients being treated 
with monoamine oxidase inhibitors  or  tricyclic  antidepressants,  or within 2 weeks of 
discontinuation of such agents, because the action of Albuterol on the vascular system 
may be potentate.
Beta-Blockers 
             Beta-adrenergic receptor blocking agents not only block the pulmonary effect of 
beta-agonists,  such  as  Albuterol  tablets,  but  may  produce  severe  bronchospasm  in 
asthmatic patients. Therefore, patients with asthma should not normally be treated with 
beta-blockers.  However,  under  certain  circumstances,  e.g.,  as  prophylaxis  after 
myocardial  infarction,  there  may  be  no  acceptable  alternatives  to  the  use  of  beta-
adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-
blockers could be considered, although they should be administered with caution.
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Diuretics 
               The ECG changes and/or hypokalemia that may result from the administration 
of  nonpotassium-sparing  diuretics  (such as  loop or  thiazide  diuretics)  can  be  acutely 
worsened by beta-agonists, especially when the recommended dose of the beta-agonist is 
exceeded.  Although the clinical  significance of these effects  is not known, caution is 
advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.
Digoxin 
              Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after 
single-dose  intravenous  and  oral  administration  of  Albuterol,  respectively,  to  normal 
volunteers  who had  received  digoxin  for  10  days.  The  clinical  significance  of  these 
findings for patients  with obstructive airway disease who are receiving Albuterol  and 
digoxin on a  chronic  basis  is  unclear.  Nevertheless,  it  would be prudent  to  carefully 
evaluate the serum digoxin levels in patients who are currently receiving digoxin and 
Albuterol.
Carcinogenesis, Mutagenesis, Impairment of Fertility
                  In a 2- year study in Sprague-Dawley rats, Albuterol sulfate caused a 
significant  dose-related  increase  in  the  incidence  of  benign  leiomyomas  of  the 
mesovarium at dietary doses of 2, 10, and 50 mg/kg (approximately 1/2, 3, and 15 times, 
respectively, the maximum recommended daily oral dose for adults on a mg/m2 basis, or, 
2/5, 2 and 10 times, respectively, the maximum recommended daily oral dose for children 
on a mg/m2 basis). In another study this effect was blocked by the coadministration of 
propranolol,  a non-selective  beta-adrenergic  antagonist.In  an 18-month  study in CD-1 
mice Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 
500 mg/kg,  (approximately 65 times  the maximum recommended daily  oral  dose for 
adults on a mg/m2 basis, or, approximately 50 times the maximum recommended daily 
oral dose for children on a mg/m2 basis). In a 22-month study in the Golden hamster, 
Albuterol  sulfate  showed no evidence  of tumorigenicity  at  dietary doses of  up to  50 
mg/kg, (approximately 8 times the maximum recommended daily oral dose for adults on 
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an mg/m2 basis, or, approximately 7 times the maximum recommended daily oral dose 
for children on a mg/m2 basis).
            Albuterol sulfate was not mutagenic in the Ames test with or without metabolic  
activation using tester strains S. typhimurium TA1537, TA1538, and TA98 or E. Coli 
WP2, WP2uvrA, and WP67. No forward mutation was seen in yeast strain S. cerevisiae 
S9 nor  any mitotic  gene conversion in  yeast  strainS.  cerevisiae  JD1 with  or  without 
metabolic activation. Fluctuation assays in S. typhimurium TA98 and E. Coli WP2, both 
with  metabolic  activation,  were  negative.  Albuterol  sulfate  was  not  clastogenic  in  a 
human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at 
intraperitoneal doses of up to 200 mg/kg.
Reproduction studies in rats demonstrated no evidence of impaired fertility at oral 
doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral 
dose for adults on a mg/m2 basis).
Pregnancy
Teratogenic Effects. Pregnancy Category C 
              Albuterol has been shown to be teratogenic in mice. A study in CD-1 mice at 
subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 3/1000, 3/100, and 
3/10 times,  respectively,  the maximum recommended  daily  oral  dose for  adults  on a 
mg/m2 basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and 
in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation 
at the lowest dose, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses 
from females treated with 2.5 mg/kg of isoproterenol (positive control) subcutaneously 
(approximately 3/10 times the maximum recommended daily oral dose for adults on a 
mg/m2 basis).
A reproduction study in Stride Dutch rabbits revealed cranioschisis  in 7 of 19 
(37%) fetuses when Albuterol was administered orally at a 50 mg/kg dose (approximately 
25 times the maximum recommended daily oral dose for adults on a mg/m2 basis).There 
are no adequate and well-controlled studies in pregnant women. Albuterol should be used 
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during pregnancy only if  the potential  benefit  justifies  the potential  risk to  the fetus. 
During worldwide marketing experience,  various congenital  anomalies,  including cleft 
palate  and limb  defects,  have  been rarely  reported  in  the  offspring  of  patients  being 
treated with Albuterol. Some of the mothers were taking multiple medications during 
their pregnancies. No consistent pattern of defects can be discerned, and a relationship 
between Albuterol use and congenital anomalies has not been established.
Tocolysis 
Albuterol  has  not  been  approved  for  the  management  of  preterm  labor.  The 
benefit/risk ratio when Albuterol is administered for tocolysis has not been established. 
Serious  adverse  reactions,  including  maternal  pulmonary  edema,  have  been  reported 
during  or  following  treatment  of  premature  labor  with  beta2-agonists,  including 
Albuterol.
Nursing Mothers
It  is  not  known whether  this  drug is  excreted  in  human milk.  Because of the 
potential  for  tumorigenicity  shown  for  Albuterol  in  some  animal  studies,  a  decision 
should be made whether to discontinue nursing or to discontinue the drug, taking into 
account the importance of the drug to the mother.
Pediatric Use
Safety  and  effectiveness  in  children  below  6  years  of  age  have  not  been 
established.
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Adverse Reactions
In clinical trials, the most frequent adverse reactions to Albuterol tablets were:
 Percent Incidence of Adverse Reactions
Reaction Percent Incidence
Central nervous system
  Nervousness 20%
  Tremor 20%
  Headache 7%
  Sleeplessness 2%
  Weakness 2%
  Dizziness 2%
  Drowsiness <1%
  Restlessness <1%
  Irritability <1%
Cardiovascular
  Tachycardia 5%
  Palpitations 5%
  Chest discomfort <1%
  Flushing <1%
 Musculoskeletal
 Muscle cramps 3%
 Gastrointestinal
 Nausea 2%
 Genitourinary
 Difficulty in micturition <1%
Rare  cases  of  urticaria,  angioedema,  rash,  bronchospasm,  and  oropharyngeal 
edema have been reported after the use of Albuterol.In addition,  Albuterol,  like other 
sympathomimetic  agents,  can  cause  adverse  reactions  such  as  hypertension,  angina, 
vomiting,  vertigo,  central  nervous  system  stimulation,  unusual  taste,  and  drying  or 
irritation  of  the  oropharynx.The  reactions  are  generally  transient  in  nature,  and  it  is 
usually not necessary to discontinue treatment with Albuterol tablets. In selected cases, 
however,  dosage may be reduced temporarily;  after  the reaction has subsided, dosage 
should be increased in small increments to the optimal dosage.
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Over dosage
The expected symptoms with over dosage are those of excessive beta-adrenergic 
stimulation  and/or  occurrence  or  exaggeration  of  any  of  the  symptoms  listed  under 
Adverse Reactions, e.g., seizures, angina, hypertension or hypotension, tachycardia with 
rates  up  to  200  beats/min,  arrhythmias,  nervousness,  headache,  tremor,  dry  mouth, 
palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia may also 
occur. As with all sympathomimetic medications, cardiac arrest and even death may be 
associated  with  abuse  of  Albuterol  tablets.  Treatment  consists  of  discontinuation  of 
Albuterol tablets together with appropriate symptomatic therapy. The judicious use of a 
cardioselective  beta-receptor  blocker  may  be  considered,  bearing  in  mind  that  such 
medication  can produce bronchospasm.  There is  insufficient  evidence  to  determine  if 
dialysis is beneficial for over dosage of Albuterol tablets. The oral median lethal dose of 
Albuterol  sulfate  in  mice  is  greater  than  2000  mg/kg  (approximately  250  times  the 
maximum recommended daily oral dose for adults on a mg/m2 basis, or, approximately 
200 times the maximum recommended daily oral dose for children on a mg/m2 basis). In 
mature  rats,  the  subcutaneous  (sc)  median  lethal  dose  of  Albuterol  sulfate  is 
approximately 450 mg/kg (approximately 110 times the maximum recommended daily 
oral  dose  for  adults  on  a  mg/m2 basis,  or,  approximately  90  times  the  maximum 
recommended daily oral dose for children on a mg/m2 basis). In small young rats, the 
subcutaneous median lethal dose is approximately 2000 mg/kg (approximately 500 times 
the  maximum  recommended  daily  oral  dose  for  adults  on  a  mg/m2 basis,  or, 
approximately 400 times the maximum recommended daily oral dose for children on a 
mg/m2 basis).
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Usual Dosage
Adults and Children Over 12 Years of Age 
The usual starting dosage for adults and children 12 years and older are 2 or 4 mg 
three or four times a day.
Children 6 to 12 Years of Age 
The usual starting dosage for children 6 to 12 years of age is 2 mg three or four 
times a day.
Dosage Adjustment Adults and Children over 12 Years of Age 
For adults and children 12 years and older, a dosage above 4 mg four times a day 
should be used only when the patient fails to respond. If a favorable response does not 
occur with the 4 mg initial dosage, it should be cautiously increased stepwise up to a 
maximum of 8 mg four times a day as tolerated.
Indications
1. Brondrodilator for in asthma, 
2. Chronic bronchitis, 
3. Emphysema.
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Table No.7 Salbutamol Sulphate Commercially Available Product 48
S.No Brand name Dosage form Strength available Company
1 Asthalin Tablet 2 mg
4mg
Cipla
Asthalin Syrup 2 mg/ 5ml Cipla
Asthalin Res-soln 2.5 mg/2.5ml Cipla
Asthalin AC-inhaler 100 mcg/ 1 puff Cipla
Asthalin MDI 100 mcg/ 1 puff Cipla
Asthalin Roto caps 30 caps Cipla
2 Asthalin –SA Tablet 8 mg Cipla
3 Salbair MDI 100 mcg/ 1 puff Lupin
4 Salbetol Tablet 2 mg
4mg
FDC
5 Salbid Tablet 2mg
4mg
Micro labs
6 Servent Inhaler 50 mcg/1 puff GSK
7 Ventirex Syrup 2 mg/5ml Unimack
8 Ventrolin CR Capsule 8mg GSK
Ventrolin Syrup 2 mg/5ml GSK
Ventrolin MDI 100 mcg/1 puff GSK
5.2 Excipients Profiles
1. Povidone 49
  Non-proprietary Name       Povidone
 Functional Category Tablet binder
                                                  Suspending agent
 Synonyms                               Polyvidone, Polyvinylpyrolidine, 
 PVP, Kollidon, Plasdone.
Chemical Name  2-pyrrolidinone, 1, ethyl homopolymer-
1- vinyl-2- pyrrollidionone polymer
74
Typical properties  
Density     1.17 to 1.18 gm/cm3
Solubility  Readily soluble in water up to 60 %,
             freely soluble in many organic solvents
Table No.8 Application of Povidone in Pharmaceutical 
Formulation
S.No Use Concentration 
1. Carrier for drug 10 - 25 %
2. Dispersing agent Up to 5 %
3.  Suspending agent Up to 5 %
4. Tablet binder, diluents, coating agent 0.5 - 5 %
2. Methylcellulose50
  Non-Proprietary Name Methyl cellulose
  Functional category Coating agent 
                Emulsifying agent
   Suspending agent 
    Tablet binder
    Viscosity increasing agent
 Synonyms   Metocel
     E 461
     Metholose
Chemical Name    Cellulose methyl ester
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Typical Properties
  Density 0.276 gm/cm3
Solubility Practically  insoluble  in  acetone  methanol  chloroform,  ethanol, 
Soluble in glacial acetic acid. In cold water methylcellulose swells 
and disperses slowly to form clear to opalescent viscous, colloidal 
dispersion.
Table No.9 Application of Methyl cellulose in Pharmaceutical 
Formulations
S.No. Use Concentration
1. Bulk laxative 5.0 to 30  %
2. Emulsifying agent 1.0 to 3.0  %
3 Sustained release tablet matrix 5.0 to 75   %
4. Tablet binder 1.0 to 5.0   %
5. Tablet coating 0.5 to 5.0   %
6 Tablet disintegrant 2.0 to 10   %
3. Hydroxyl propyl methyl cellulose51
  
 Non-proprietary Name Hypromellose
Hydroxyl propyl methylcellulose
  Functional category Suspending agent 
Coating agents
Tablet binder
Film former
  Synonyms Methyl hydroxyl propyl cellulose
Propylene glycol, ether cellulose
Hydroxyl propyl methyl cellulose
 Chemical Name Cellulose 2- hydroxyl propyl methyl ether 
cellulose, hydroxyl propyl methyl ether.
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 Typical properties
Density 0.341 gm/cm3
Solubility Soluble  in  cold  water  forming  viscous  colloidal  
solution.  Insoluble  in  alcohol,  ether  and  
chloroform.
 Grade HPMC K 100 M
HPMC K 4 M
HPMC K 15M 
HPMC k100 LVP 
 Viscosity HPMC K 100 M    - 8000 to 120 000 m pas
              HPMC K 4 M       - 3000 to 5600     m pas
Application of HPMC in Pharmaceutical Formulation
Film former in tablets film coating. Lower viscosity grades are used in aqueous 
film coating. Higher viscosity grades may be used to retard the release of drugs from a 
matrix a levels of 10 - 80 %w/w in tablet and capsule. Depending up on the viscosity 
grade,  concentration of 2 -  20% w/w are used for film forming solution to film coat  
tablet.  Lower viscosity grade are used in aqueous film coating solution,  while higher 
viscosity grades are used with organic solvent.
4. Ethyl cellulose 52
Non-Proprietary Name Ethyl cellulose
Synonyms  Ethocel
Surelease
Agualon
Chemical Name Cellulose ethyl ether
Functional category Coating agents 
Tablet binder
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Tablet filler
Typical properties
Density 0.400 gm/cm3
            Solubility     Ethyl cellulose in glycerin propylene glycol and water. 
Freely soluble in chloroform, methyl acetate and 
tetra hydro furan
Table No.10 Application of Ethyl cellulose in Pharmaceutical Formulation
S. No Use Concentration
1. Micro encapsulation 10.0 to 20 %
2. Sustained release tablet coating 03.0 to 20 %
3. Tablet coating 01.0 to 3.0 %
5. Polymethacrylates53
  Non-proprietary Name             Methylic acid copolymer
 Synonyms             Eurasia 
   Kollicoat MAE 30 D
          Kollicoat MAE 30 DP
 Functional Category Film former 
Tablet binder
Tablet diluents
Polymethacrylic are synthetic cationic and anionic polymer of methyl amino ethyl 
methacrylic  acid  and  methacrylic  acid  esters  in  various  ratios.  Several  type  of 
commercially  available  and  may  be  obtained  as  dry  powder  aqueous  dispersion  or 
organic solution Eudragit S 100, is a white free flowing powder with at least 95 % dry 
polymer. Eudragit RPS, are fine white powder with a slight amine like odour.
Typical properties
Density
Eudragit RSPO  0.816 to 0. 836 gm/cm3
Solubility
Eudragit RSPO is soluble in acetone and alcohol.
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Eudragit S 100 is soluble in intestinal fluid pH 7.0. 
Eudragit RSPO aqueous dispersion of polymethacrylates which has 
low permeability with sustained release effect.
Application of Polymethacrylate in Pharmaceutical Formulations
Polymethacrylate  are primarily used in oral  capsule and tablets  formulation as 
enteric  coating  agents.  Eudragit  RSPO is  used  to  form water  insoluble  film coat  for 
sustained release formulation. Eudragit RL 100, Eudragit RSPO, Eudragit RS 100 were 
found to have buoyancy hence suitable for floating drug delivery. Polymethacrylate are 
used as binder in both aqueous and organic wet granulation. Larger quantities ( 5 - 20 % ) 
of the drug polymer are used to control the active substance from the tablet matrix.
6. Stearic acid54
  Non-proprietary Names Stearic acid
  Synonyms Emersol
Hystrene
Kortacid 
Pristerene 
 Chemical Name Octa decanoic acid
 Functional category Emulsifying agent
Tablet capsule lubricant
  Typical properties
Density 0.537 gm/cm3
Solubility Freely  soluble  in  benzene,  carbon tetra  chloride,  
chloroform,  ether,.  Soluble  inn  ethanol, 
hexane, and polyethylene glycol. Insoluble in 
water.  
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Table No.11 Application of Stearic acid in Pharmaceutical Formulations
S. No Use Concentration
1 Ointments and creams 1 - 20  %
2. Tablet lubricant 1 - 3 .0 %
7. Magnesium sterate55
   Non-proprietary Name Magnesium state
   Functional category Tablet and capsule lubricant
Glidant, Anti adherent
   Typical properties
Density 1.03 to 1.08 gm/cm3
Solubility Insoluble in water, alcohol and ether and slightly soluble 
in hot alcohol and benzene
Application of Magnesium Sterate in Pharmaceutical Formulations
Tablet anti-adherent in the concentration of 0.25 to 20 percent
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  6. Material and Methods
6.1 List of Instruments 
Table No.12 List of Instruments Used
S. No Instrument  Name Company 
1. Digital weighing balance Sartorius
2. Tray drier Mixofill
3. Rotary tablet punching machine Rimeck minipress
4. pH  Meter Thermovorision 
5. Tap density tester Electrolab
6. Mechanical sieve shaker Retsch
7. Friability tester Roche 
8. Hardness tester Pfizer
9. UV-Visible spectrophotometer Shimandzu
10. Dissolution tester USP Electrolab
11 Environment  Chamber Heco
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6.2 List of Excipients and Chemicals
Table No.13 List of Excipients and Chemical Used
S. No Excipients Company 
1 Methyl cellulose Nice chemical Pvt. Ltd.,
2. HPMC ( K 100 M, K 4 M) Kemphasol
3. Ethyl Cellulose Loba chemice
4. Eudragit RSPO Rohmgmbh,Germany
5. Stearic acid Lancaster synthesis
6 Sodium bicarbonate Hi-pure fine chem. Industries
7 Citric acid Reachem laboratory chemicals Pvt. Ltd.,
8. Microcrystalline cellulose Hi-pure Fine Chemical industries
9 Magnesium striate Reachem  laboratory chemicals
10. Talc Nice chemical Pvt. Ltd.,
11. Isopropyl alcohol Micro fine chemicals
List of Reagents
0.1 N Hydrochloric acid 57
8.5 ml of Concentrated Hydrochloric acid is dissolved in 1000 ml of distilled 
water.
Stimulated Gastric Fluid pH 1.2 (without pepsin) 58
0.2  gm  of  sodium  chloride,  0.07  ml  of  concentrated  hydrochloric  acid  were 
mixed, to this mixture 100 ml of distilled water was added and final solution was adjusted 
to pH 1.2 with diluted sodium hydroxide solution.
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6.4 Formulation Development and Evaluation of Floating Matrix Tablet Containing 
Salbutamol Sulphate
Stage -1
Literature Survey
Stage - 2
   Active Sourcing and Evaluation
Stage - 3
Active Purchasing
Stage - 4
Formulation Process
Stage – 5
Optimization of Formulation Process
Stage - 6
Formulation of Floating Matrix Tablet
 1. Hydrophilic Floating Matrix Tablets
   2. Insoluble Floating Matrix Tablets
   3. Combined Floating Matrix Tablets
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Stage - 7
Evaluation Floating Matrix Tablets
Stage - 8 
Result and Discussion
Stage - 9
      Summary and Conclusion
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6.5 Standard Curve for Salbutamol sulphate59
Standard Curve for Salbutamol sulphate in Simulated Gastric fluid pH 1.2
Requirement
Salbutamol sulphate
Stimulated gastric fluid with pH 1.2 
Procedure
Weigh  accurately  100mg  of  Salbutamol  suphate  is  dissolved  in  100ml  of 
simulated gastric fluid from this solution 0.5, 1, 1.5, 2, 2.5,3 ml of drug solution was 
made up to 10ml with simulated gastric fluid. The absorbance was measured at 276 nm 
using stimulated gastric fluid as blank. The above procedure was repeated for three times 
and  average  absorbance  was  calculated.  The  standard  curve  was  made  by  plotting 
concentration Vs absorbance.
Table No.14 Standard Curve of Salbutamol sulphate in
Simulate Gastric Fluid pH 1.2
S.No. Concentration in mcg/ml Absorbance at 276 nm
1 50 0.270
2 100 0.487
3 150 0.697
4 200 0.956
5 250 1.183
6 300 1.397
*Average value of three observations 
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Figure No.8 Standard Curve of Salbutamol Sulphate in 
Simulated Gastric Fluid pH 1.2
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Standard Curve for Salbutamol sulphate in Distilled Water
Requirement
Salbutamol sulphate
Distilled Water
Procedure
Weigh accurately 100mg of Salbutamol suphate is dissolved in 100ml of distilled 
water from this solution 0.5, 1, 1.5, 2, 2.5,3 ml of drug solution was made up to 10ml 
with distilled water. The absorbance was measured at 276 nm using distilled water as 
blank. The above procedure was repeated for three times and average absorbance was 
calculated. The standard curve was made by plotting concentration Vs absorbance
Table No.15 Standard Curve of Salbutamol sulphate in Distilled water
S.No. Concentration in mcg/ml Absorbance at 276 nm
1 50 0.336
2 100 0.580
3 150 0.889
4 200 1.145
5 250 1.427
6 300 1.740
*Average value of three observations 
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Figure No.8 Standard Curve of Salbutamol Sulphate in 
Simulated Gastric Fluid pH 1.2
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6.6 Formulation Development of Floating Matrix Tablets
Floating Matrix Tablets
A modified release drug delivery system with prolonged gastric residence time in 
the stomach is of particular interest for dug 
 The drug with an absorption window in the stomach or in the upper art 
of the small intestine
 The drug which are locally active in the stomach,
 The drug which are unstable in the intestinal or colonic environment,
 The drug with low solubility at high pH value,
 The drug that undergo first pass metabolism.
Process Flow Chart
Wet granulation method
Drug
Mixing
Polymer Excipients 
Granulating agent
Granulation
Sieving
Drying
Mixing   Lubricant
        Glidant 
Compression
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Approaches 
Floating matrix tablets were formulated by two different methods by using 
various matrix forming materials.
Hydrophilic Floating Matrix Tablets
Matrix former    - Methylcellulose, Hydroxyl propyl methylcellulose 
      (K100 M, K 4 M) 
Approach      - Non-effervescent method
Buoyancy agent - Methylcellulose, Hydroxyl propyl methylcellulose  
      (K 100 M, K 4 M)
Insoluble Floating Matrix Tablets
Matrix former      - Ethyl cellulose, Eudragit RSPO
Approach      - Effervescent method
Buoyancy agent   - Citric acid, Sodium bicarbonate
      
Combined Floating Matrix Tablets
Matrix former     - Hydrophilic polymer (HPMC K100M)
                                  Hydrophobic polymer (Ethyl cellulose, Eudragit RSPO)
Approach    - Non-effervescent method
Buoyancy agent -Hydrophilic polymer.
1. Hydrophilic Floating Matrix Tablets
Matrix former    - Methylcellulose, Hydroxyl propyl methylcellulose 
     (K100 M, K 4 M)
Formulation Process
The  hydrophilic  floating  matrix  tablets  were  formulated  by  incorporating  the 
active  dug  with  hydrocolloids  like  methylcellulose,  hydroxypropyl  methylcellulose, 
microcrystlline cellulose and other excipients were added and compressed in to tablet.
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2. Insoluble Floating Matrix Tablets
Matrix former    - Ethyl cellulose, Eudragit RSPO
Formulation Process
The insoluble floating tablets were formulated by using the gas-forming agent. 
The concentration of the gas-forming agents were optimized for its floating behavior in 
stomach. The optimized concentration of the citric acid and sodium bicarbonate are 
incorporated with hydrophobic polymer, microcrystalline cellulose other excipents were 
added and compressed in to tablet.
3. Combined Floating Matrix Tablets
Matrix former    - Hydrophilic polymer (HPMC K100M)
                                  Hydrophobic polymer (Ethyl cellulose, Eudragit RSPO)
Formulation Process
The combined floating matrix tablets were formulated by incorporating the active 
dug with hydrophilic polymer  like Hydroxypropylmethylcellulose (HPMC K100M) and 
hydrophobic polymer like ethyl cellulose and eudragit RSPO, microcrystalline cellulose 
and other excipients were added and compressed in to tablets.
6.7 Formula for Formulation of Hydrophilic Floating Matrix Tablets
Trial –I
Table No.16 Formulation No.1
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Methyl cellulose (25 %) 37.50
3. Microcrystalline cellulose 85.50
4. PVP-K30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium stearate 02.25
7. Talc 01.50
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Table No.17 Formulation No.2
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Methyl cellulose ( 50 % ) 75.00
3. Microcrystalline cellulose 48.50
4. PVP-K30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
Table No.18 Formulation No.3
S. No Ingredients
Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Methyl cellulose (75 % ) 112.50
3. Microcrystalline cellulose 10.50
4. PVP-K30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium Sterate 02.25
7. Talc 01.50
Formulation Process
 The amount of hydrocolloids were optimized by varying the concentration of the 
polymer 
F1 - 25 percent w/w
F2 - 50 percent w/w
` F3 - 75 percent w/w
Weighed quantity of salbutamol  sulphate,  methylcellulose and microcrystalline 
cellulose were thoroughly mixed and passed through the sieve no. 60, granulation with a 
solution of calculated quantity of PVP-K30 in sufficient quantity of isopropyl alcohol. 
The wet mass passed through sieve no.10 and dried at 45°C-55 °C for 2 hours. The dried 
granules were sized by sieve no.22 and mixed with magnesium streate  and talc.  The 
granules are compressed in to tablets  on a 10 station rotary Rimeck minipress tablet-
punching machine with 7 mm punch size. The tablets were punched in to two different 
hardness and shape, 5 kg/cm2, 10 kg/cm2and round, oval shape respectively. 
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Observation
Harness about 5 kg/cm2 - Floating lag time is in seconds
Hardness about 10 kg/cm2 - Floating lag time is in minutes
Round shape - Swelling is good as compared with oval shape,  
   better floating   behaviors.
Trial –II
Table No.19 Formulation No-4
S. No Ingredients Quantity   for one tablet in mg
1 Salbutamol sulphate 16.00
2 HPMC K 4M ( 25 % ) 37.50
3. Microcrystalline cellulose 85.50
4. PVP-K 30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
Table No.20 Formulation No.5
S. No Ingredients Quantity   for one tablet in mg
1 Salbutamol sulphate 16.00
2 HPMC K 4 M ( 50 % ) 75.00
3. Microcrystalline cellulose 48.50
4. PVP-K 30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
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Table No.21 Formulation No.6
S. No Ingredients Quantity   for one tablet in mg
1 Salbutamol sulphate 16.00
2 HPMC K 4 M (75 % ) 112.50
3. Microcrystalline cellulose 10.50
4. PVP-K 30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
Table No.22 Formulation No.7
S. 
N
o
Ingredients Quantity   for one tablet in mg
1 Salbutamol sulphate 16.00
2 HPMC K 100 M (25 %) 37.50
3. Microcrystalline cellulose 85.50
4. PVP-K 30 (4.8 %) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
Table No.23 Formulation No.8
S. No Ingredients Quantity   for one tablet in mg
1 Salbutamol sulphate 16.00
2 HPMC K100 M (50 %) 75.00
3. Microcrystalline cellulose 48.50
4. PVP-K 30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
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Table No.24 Formulation No.9
S. No Ingredients Quantity   for one 
tablet in mg
1 Salbutamol sulphate 16.00
2 HPMC K 100 M (75 %) 112.50
3. Microcrystalline cellulose 10.50
4. PVP-K 30 ( 4.8 % ) 07.20
5. Isopropyl alcohol q.s
6. Magnesium striate 02.25
7. Talc 01.50
Formulation Process
The  amount  of  HPMC  (K100M,  K4M)  was  optimized  by  varying  the 
concentration 25, 50, 75 % w/w of its total weight of the tablet.  Weighed quantity of 
salbutamol  sulphate,  methylcellulose  and  microcrystalline  cellulose  were  thoroughly 
mixed  and passed  through the  sieve  no.60,  granulation  with  a  solution  of  calculated 
quantity of PVP-K 30 in sufficient quantity of isopropyl alcohol. The wet mass passed 
through sieve no.10 and dried at 45-55 oC for 2 hours. The dried granules were sized by 
sieve no.22 and mixed with magnesium sterate and talc. The granules are compressed in 
to tablets on a 10 station rotary Rimeck minipress tablet-punching machine with 7 mm 
punch size. 
Observation 
In vitro  drug release of the floating matrix tablets were showed their maximum 
amount of drug released before 12 hours
Formula for Formulation of Hydrophilic Floating Matrix Tablets with Stearic acid
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Trial –III
Table No.25 Formulation No.10
S. No Ingredients Quantity for one tablet in 
mg
1 Salbutamol sulphate 16.00
2 Stearic acid (25 %) 37.50
3. Microcrystalline cellulose 85.50
4. PVP K 30 (4.8 %) 07.20
5. Isopropyl alcohol q.s
6. Magnesium stearate 02.25
7. Talc 01.50
Table No.26 Formulation No.11
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Stearic acid 25% 37.50
3. HPMC  K 100M  50% 75.00
4. Microcrystalline cellulose 10.00
5. PVP-K 30 ( 4.8 % ) 07.20
6. Isopropyl alcohol q.s
7. Magnesium state 02.25
8. Talc 01.50
Table No.27 Formulation No.12
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Stearic 50% 75.00
3. HPMC  K 100M  25% 37.50
4. Microcrystalline cellulose 10.00
5. PVP-K 30 ( 4.8 % ) 07.20
6. Isopropyl alcohol q.s
7. Magnesium state 02.25
8. Talc 01.50
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Formulation Process
 Weighed  quantity  of  salbutamol  sulphate,  stearic  acid,  HPMC  K100M  and 
microcrystalline cellulose were thoroughly mixed and passed through the sieve no. 60, 
granulation with a solution of calculated quantity of PVP-K30 in sufficient quantity of 
isopropyl alcohol. The wet mass passed through sieve no.10 and dried at 45-55°C for 2 
hours. The dried granules were sized by sieve no.22 and mixed with magnesium streate 
and  talc.  The  granules  are  compressed  in  to  tablets  on  a  10  station  rotary  Rimeck 
minipress tablet-punching machine with 7 mm punch size. 
Observation 
In  addition  of  stearic  acid  in  hydrophilic  floating  matrix  tablets  was  shows 
sustained the drug release from the matrix tablet and maintain the floating behavoiurs of 
the tablets up to 24 hours by retarding the penetration of water in to the floating matrix 
tablets.
6.8 Formula for Formulation of Insoluble Floating Matrix Tablets
Trial –IV
Table No.28 Formulation No.13
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Ethyl cellulose (25 %) 37.50
3. Microcrystalline cellulose 73.50
4. Citric acid 02.00
5. Sodium bicarbonate 10.50
6. PVP K 30 ( 4.8 % ) 07.20
7. Isopropyl alcohol q.s
8. Magnesium stearate 02.25
9. Talc 01.50
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Table No.29 Formulation No.14
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Eudragit RSPO  (25 %) 37.50
3. Microcrystalline cellulose 73.50
4. Citric acid 02.00
5. Sodium bicarbonate 10.50
6. PVP K 30 ( 4.8 % ) 07.20
7. Isopropyl alcohol q.s
8. Magnesium stearate 02.25
9. Talc 01.50
Formulation Process
 Weighed  quantity  of  salbutamol  sulphate,  HPMC K100M, citric  acid,  sodium 
bicarbonate and microcrystalline cellulose were thoroughly mixed and passed through the 
sieve no.60, granulation with a solution of calculated quantity of PVP-K30 in sufficient 
quantity of isopropyl alcohol. The wet mass passed through sieve no.10 and dried at 45-
55°C  for  2  hours.  The  dried  granules  were  sized  by  sieve  no.22  and  mixed  with 
magnesium streate and talc. The granules are compressed in to tablets on a 10 station 
rotary Rimeck minipress tablet-punching machine with 7 mm punch size. 
Observation
The insoluble floating  matrix  tablets  were showed their  floating behavoiurs in 
simulated gastric fluid up to 12 as in the form of disintegrated particle instead of tablet. 
The  in  vitro  drug release  of  the  floating  matrix  tablets  were  showed their  maximum 
amount of drug released before 12 hours
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6.9 Formula for Formulation of Combined Floating Matrix Tablets
Trial –V
Table No.30 Formulation No.15
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Ethyl cellulose (25 %) 37.50
3. HPMC K 100M (50%) 75.00
4. Microcrystalline cellulose 10.50
5. PVP K 30 ( 4.8 % ) 07.20
6. Isopropyl alcohol q.s
7. Magnesium stearate 02.25
8. Talc 01.50
Table No.31 Formulation No.16
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Ethyl cellulose (50 %) 75.00
3. HPMC K 100M (25 %) 37.50
4. Microcrystalline cellulose 10.50
5. PVP K 30 ( 4.8 % ) 07.20
6. Isopropyl alcohol q.s
7. Magnesium stearate 02.25
8. Talc 01.50
Table No.32 Formulation No.17
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Eudragit RSPO (25 %) 37.50
3. HPMC K 100M (50%) 75.00
4. Microcrystalline cellulose 10.50
5. PVP K 30 ( 4.8 % ) 07.20
6. Isopropyl alcohol q.s
7. Magnesium stearate 02.25
8. Talc 01.50
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Table No.33 Formulation No.18
S. No Ingredients Quantity for one tablet in mg
1 Salbutamol sulphate 16.00
2 Eudragit RSPO(50 %) 75.00
3. HPMC K 100M (25 %) 37.50
4. Microcrystalline cellulose 10.50
5. PVP K 30 ( 4.8 % ) 07.20
6. Isopropyl alcohol q.s
7. Magnesium stearate 02.25
8. Talc 01.50
Formulation Process
 Weighed  quantity  of  salbutamol  sulphate,  HPMC  K100M,  ethyl  cellulose, 
eudragit RSPO and microcrystalline cellulose were thoroughly mixed and passed through 
the  sieve  no.60,  granulation  with  a  solution  of  calculated  quantity  of  PVP-K30  in 
sufficient quantity of isopropyl alcohol. The wet mass passed through sieve no.10 and 
dried at 45 - 55°C for 2 hours. The dried granules were sized by sieve no.22 and mixed  
with magnesium streate  and talc.  The granules  are  compressed  in  to  tablets  on a  10 
station rotary Rimeck minipress tablet-punching machine with 7 mm punch size. 
Observation
In vitro  drug release of the floating matrix tablets were showed their maximum 
amount of drug released before 12 hours
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6.10 Evaluation of Floating Matrix Tablets
API Consideration
Angle of Repose60
       It  is  defined as the maximum angle that  can be obtained between the free 
standing of the powder heap and horizontal plane, which is given by the equation
  =tanӨ -1H/R
Where, 
                  - Angle of reposeӨ
                 H-Height of the pile
                 R- Radius of the base of the conical pile
Procedure 
          Weighed quantity of the granules was passed through a funnel kept at a height of 1  
cm from the base. The powder is passed till it forms a heap and touches the tip of the 
funnel. The radius was measured and angle of repose was calculated. 
 =tanӨ -1H/R
Limit
S.No Angle of repose Type of flow
1 Less than 25 Excellent
2 25 to 30 Good
3 30 to 40 Passable
4 Above 40 Very poor
Bulk density 
      It refers to a measurement to desirable packing of particles bulk density is used to 
determine the amount of the drug that occupies the volumes in mg/ml
Pi = m/vi
Where, 
m - The mass of blend
Vi- Untapped volume
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Procedure
      Weighed quantity of powder was transferred in to a 100 ml measuring cylinder  
without tapping during the transfer. The volume occupied by the powder was measured 
by 
Pi = m/vi
Compressibility index
         Weighed quantity of the powder was transferred to 100ml of graduated measuring 
cylinder and subjected for tapping in a tap density tester (electro lab). The differences 
between two taps should be less than 2 percent
The compressibility index
CI = Vi-Vt / Vi × 100
Where,
        Vi- untapped volume
        Vt- tapped volume
Limit
S.No Carr’s index Type of flow
1 5 to 15 Excellent
2 12 to 16 Good
3 18 to 23 Fair to Passable
4 23 to 25 Poor
5 33 to 38 Very poor
6 Above 40 Extremely poor
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Hardness61
      Although  there  is  no  official  test  for  tablet  hardness  this  property  must  be 
controlled  during  production  to  ensure  that  the  product  is  firm  enough  to  withstand 
handling  without  breaking,  chipping etc.,  the  hardness  of  a  tablet  is  indicative  of  its 
tensile strength and is measured in term of pressure required to crush it when placed on 
its edge. Hardness of about 5 kg/cm2 is considered to be minimum for uncoated tablets 
for mechanical  stability.  The hardness had influence on disintegration and dissolution 
times. Hardness is the factor that affects the bioavailability.
Friability62 
        Friability generally refers to loss in weight of tablets in the container due to  
chipping, abrasion, and erosion. The standard device available is “Friabilators” (Consist 
of circular plastic chamber, a divided into two compartments. The chamber rotates at a 
speed of 25 r.p.m and drops the tablets by distance of 15 cm). The weight loss should not  
be more than one percent.
Formula
        Percentage Friability = (initial weight-final weight/initial weight) Χ 100
Procedure
       10 tablets are weighed and transferred in to Friabilator. Then after 100 revolutions  
per minute the tablets were unloaded and weight of the tablets was noted. The difference 
should not exceed one percent.
Floating Behaviors of Floating Matrix Tablets
     Floating  properties  of  tablets  were  evaluated  in  a  dissolution  vessel  
(USP dissolution tester) filled with 900 ml of Simulated Gastric Fluid pH 1.2 and paddle 
rotation  speeds  of  100  rpm  were  tested.  Temperature  was  maintained  at  37±0.5°C. 
Floating  tablets  placed  in  the  media  and  the  floating  time  was  measured  by  visual 
observation.
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In  vitro Drug release Profiles
           The drug release rate from the floating matrix tablets was carried out by the  
USP 24 dissolution test apparatus II (paddle method, Electrolab) was used for this test, 
900ml of simulated gastric fluid (pH1.2) and distilled water was introduced in to the 
vessel  of the apparatus.  The medium was warmed to 37°C ± 0.5°C. The paddle was 
rotated at the speed of 100 rpm. Tablet was placed in the jar were used for experiment, 
sample were taken at regular time intervals of 0.25,0.50,0.75,1,2,3,4,5,6,7,8,9,10,11,12 
up to 24 hours, 5 ml of samples from the medium was withdrawn and the same volume of 
fresh dissolution medium was replaced to maintained the sink condition. The absorbance 
of the sample solution was measured at 276 nm. This test was carried out until there was 
no further release.
6.11 ACCELERATED    STABILITY    STUDIES
Stability 63
         Stability is officially defined as the time lapse during which the drug product 
retains  the  same  properties  and  characteristics  that  is  possessed  at  the  time  of 
manufacture. This process begins at early devolvement phases.
       Instability in modern formulation is often detectable  only after considerable 
storage period under normal condition. To assess the stability of a formulated product its 
usual to expose it to high stress conditions to enhance its detoriation and therefore the 
time required for testing is reduce  common high stress like temperature and humidity. 
This will eliminate unsatisfactory formulation.
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Strategy of Stability Testing 
1. The study of drug decomposition kinetics
2. The development of stability dosage form.
3. Establishment of expiration date for commercially available drug product is some 
of the needs of stability testing.
4. Data form stability studies should be provided on atleast three primary batches of 
the drug product. 
5. The batches should be manufactured to a minimum of pilot scale.
6. Important point of view of the safety of the patient,  patient relieves a uniform 
dose of drug throughout the shelf life of the product.
Table No.34 The Stability Storage Condition
S.No  Study Storage condition Minimum period
1. Long-term study 25° C ± 2° C 
60 % ± 5% RH
12 month
2. Intermediate study 30 ° C ± 2° C
60 % ±5 % RH
6 month
3. Accelerated study 40° C ± 2 ° C
75% ±5 % RH
6 month
ICH (International Conference on Harmonization) Guidelines
105
 Specification
1. 5% potency loss from initial assay of batch
2. Any specification degradation that exceed specification
3. Product failing out of pH limit
4. Dissolution out of specification for 12 minutes
5. Failure to meet specification for appearances and physical properties
Any one condition is observed then the stability of the batch is failed.
Procedure
    Selected batches were placed in a high density polyethylene container, blister pack, 
stripe pack etc. they are kept in stability chamber maintained at 40°C and 75 % RH. The 
stability studies were carried out for a period of one month. The tablets were tested and 
checked for the above mention specification.
106
7. Results and Discussion
Preformulation Studies
Drug Identification
      Method - Spectrophotometer method (UV)
Table No.35 UV- Absorbance of Salbutamol sulphate in 0.1 N HCL
S. No Concentration in mcg/ml Absorbance at 276nm
1 50 mcg/ml 0.379
2. 300 mcg/ml 1.673
    
Table No.36 UV-Absorbance of Salbutamol Sulphate in water
Table No.37 UV-Absorbance of Salbutamol sulphate in Different Solvent
S. No Medium Wave length
1. 0.1 N HCL 225 nm-E 1% 1cm value 310
276 nm-E 1% 1cm value 60
2. pH -2 276nm
3. pH -12 296 nm
4. 90 % neutral ethanol 276nm, 298nm
Discussion
 
• The  UV-  absorbances  of  the  Salbutamol  sulphate  were  performed  at 
different  concentration  in  different  medium and their  wavelength  were 
found and compared with monograph. 
S. No Concentration in mcg/ml Absorbance at 276 nm
1 50 mcg/ml 0.290
2. 300 mcg/ml 1.621
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Figure No.10 UV-Absorbance of Salbutamol Sulphate
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Figure No.11 UV-Absorbance of Salbutamol Sulphate in 0.1 N HCL
(Concentration 50 mcg/ml)
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Figure No.12 UV-Absorbance of Salbutamol Sulphate in 0.1 N HCL
(Concentration 300 mcg/ml)
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Figure No.13 UV-Absorbance of Salbutamol Sulphate in Water
(Concentration 50 mcg/ml)
Figure No.14 UV-Absorbance of Salbutamol Sulphate in Water
(Concentration 300 mcg/ml)
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Infra-Red Spectrum
Table No.38 IR Spectrum of Salbutamol Sulphate 
S.No Wave number in cm-1 Functional Group
1 3416 OH and NH  Stretching
2 2810 -CH  Aliphatic
3 2375 -CH for – CH2 - Chain
4 1610-1592 Aromatic ring C= C Stretching
5 1370,1270,1190 Phenolic C-O Stretching
6 1150 and lower Aromatic CH Bending
7 1385 S=O Asymmetric 
Discussion
• The structure of Salbutamol sulphate was confirmed by IR spectrum and 
the spectrum was compared with standard graph in monograph.
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                      H2SO4
Figure No.15 FT-IR Spectrum of Salbutamol Sulphate (KBr pellet method)
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Figure No.16 FT-IR Spectrum of Salbutamol Sulphate (KBr pellet method)
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API   CONSIDERATION
Flow Property Characterization of Salbutamol Sulphate Floating Matrix Tablets
The various flow property characterizations of Salbutamol sulphate floating 
matrix tablets were evaluated and the results were listed in the table no.39, 40, and 41.
Table No. 39 Flow property and Physical Parameters of Salbutamol sulphate 
Hydrophilic-Floating Matrix Tablets
 
Formulation 
code
*Bulk density
gm/cm3
*Angle of repose Carr’s index
%
Type of flow
F1 0.332 22° 37’ 14.2 Excellent
F2 0.357 27° 38’ 14.7 Excellent
F3 0.395 22° 22’ 12.9 Excellent
F4 0.370 24° 50’ 14.5 Excellent
F5 0.350 23° 48’ 11.5 Excellent
F6 0.384 23° 13’ 16.12 Excellent
F7 0.352 21° 34’ 11.76 Excellent
F8 0.333          20° 36’ 14.70 Excellent
F9 0.319 25° 27’ 16.12 Excellent
F10 0.337 22° 57’ 15.15 Excellent
F11 0.348 20° 36’ 15.60 Excellent
F12 0.333 22° 37’ 14.70 Excellent
* Average value of three observations.
Discussion
The values of angle of repose and Carr’s index were less than 25° and 15 % 
respectively, hence the flow properties of the all formulations complied within 
the limits.
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Table No.40 Flow Property and Physical Parameters of Insoluble
 Floating Matrix Tablets
Formulation 
code
*Bulk density 
gm/cm3
*Angle of repose Carr’s index 
%
Type of flow
F13 0.353 22° 37’ 14.50 Excellent
F14 0.334 21° 38’ 14.00 Excellent
* Average value of three observations.
Discussion
The values of angle of repose and Carr’s index were less than 25°   and 15 % 
respectively; hence the flow properties of the all formulations complied within 
the limits.
Table No.41 Flow Property and Physical Parameters of Combined 
Floating Matrix Tablets
Formulation 
code
*Bulk density 
gm/cm3
*Angle of repose
Carr’s index
%
Type of flow
F15 0.357 22° 22’ 13.00 Excellent
F16 0.395 24° 56’ 12.00 Excellent
F17 0.370 23° 52’ 12.50 Excellent
F18 0.384 20° 36’ 13.50 Excellent
* Average value of three observations.
Discussion 
The values of angle of repose and Carr’s index were less than 25° and 15 % 
respectively,  hence  the  flow properties  of  the  all  formulations    complied 
within the limits.
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Evaluation of Floating Matrix Tablets
Tablet No.42 Physical Parameters of Hydrophilic Floating Matrix Tablets
S.No Formulation 
code
Weight variation *Hardness 
kg/cm2 
Friability in %
1 F1 Complies with IP 5.0 ±0.31 0.39
2 F2 Complies with IP 5.2 ±0.30 0.25
3 F3 Complies with IP 5.2 ±0.46 0.33
4 F4 Complies with IP 4.8 ±0.65 0.43
5 F5 Complies with IP 4.8 ±0.46 0.25
6 F6 Complies with IP 5.0 ±0.44 0.29
7 F7 Complies with IP 4.9 ±0.41 0.21
8 F8 Complies with IP 5.3 ±0.62 0.25
9 F9 Complies with IP 4.9 ±0.58 0.31
10 F10 Complies with IP 4.9 ±0.20 0.33
11 F11 Complies with IP 5.0 ± 0.74 0.19
12 F12 Complies with IP 5.1 ± 0.25 0.13
* Average value of six observations.
Discussion
The weight variation and friability of the prepared tablet formulations 
complied within the limits.
Tablet No.43 Physical Parameters Insoluble Floating Matrix Tablets
S.No Formulation 
code
Weight variation *Hardness 
kg/cm2 
Friability in %
1 F13 Complies with IP 5.2 ±0.30 0.39
2 F14 Complies with IP 4.8 ±0.65 0.45
* Average value of six observations.
Discussion
The weight variation and friability of the prepared tablet formulations 
complied within the limits.
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Tablet No.44 Physical Parameters Combined Floating Matrix Tablets
S.No Formulation 
code
Weight variation *Hardness 
kg/cm2 
Friability in 
percentage
1 F15 Complies with IP 4.8 ±0.45 0.45
2 F16 Complies with IP 5.0 ±0.44 0.35
3 F17 Complies with IP 4.9 ±0.41 0.33
4 F18 Complies with IP 5.3 ±0.62 0.30
* Average value of six observations.
Discussion
•The weight variation and friability of the prepared tablet formulations 
complied within the limits.
Floating Properties of Floating Matrix Tablets
Table No.45 Floating Behaviours of Hydrophilic Floating Matrix Tablets
 (Simulated Gastric Fluid pH 1.2)
Formulatio
n code
Hardness 
kg/cm2 
*Lag time 
in seconds
Hardness 
kg/cm2 
*Lag time
in minutes
Duration of 
floating in hours
F1 5 kg/cm2 5.0±0.12 10 kg/cm2 25±1.6 20
F2 5 kg/cm2 4.5±0.50 10 kg/cm2 20±1.5 24
F3 5 kg/cm2 5.0±0.60 10 kg/cm2 15 ±1.5 24
* Average value of three observations.
Discussion 
•The tablets which have hardness of about 5kg/cm2 showed lesser lag time 
lower (in seconds) than the tablet which have hardness of  about 10 kg/cm2 
(lag  time  in  minutes),  due  to  reduction  of  porosity  of  the  material  at 
highest hardness (evidence of the floating behaviours given in the table 
no.45 and figure no.17,18 and19.
•Based on these observations  the  other  formulations  were formulated  with 
hardness of about 5 kg/cm2 .
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Figure No.17 Effect of Hardness and Effect of Stearic acid on floating behaviors of 
Hydrophilic Floating Matrix tablet and in Simulated Gastric Fluid pH 1.2 at 0 h
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Figure No.18 Effect of Hardness and Effect of Stearic acid on floating behaviors of 
Hydrophilic Floating Matrix tablet and in Simulated Gastric Fluid pH 1.2 at 12thhr
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Figure No.19 Effect of Hardness and Effect of Stearic acid on floating behaviors of 
Hydrophilic Floating Matrix tablet and in Simulated Gastric Fluid pH 1 at 24th hr
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Table No.46 Floating Behaviours of Hydrophilic Floating Matrix Tablets (Simulated Gastric Fluid pH 1.2)
FC *Lag time 
in seconds                                                                       *Duration of floating time in hours
1 2 3 4 5 6 7 9 8 1
0
1
1
1
2
1
3
14 15 1
6
1
7
18 19 20 21 22 23 24
F1 5.0 ±0.10 + + + + + + + + + + + + + + + + + + + + - - - -
F2 4.5±0.50 + + + + + + + + + + + + + + + + + + + + + + + +
F3 5.0±0.60 + + + + + + + + + + + + + + + + + + + + + + + +
F4 4.6±0.40 + + + + + + + + + + + + + + + + + + + + - - - -
F5 5.0 ±0.50 + + + + + + + + + + + + + + + + + + + + + + + +
F6 5.0±0.40 + + + + + + + + + + + + + + + + + + + + + + + +
F7 5.0±0.20 + + + + + + + + + + + + + + + + + + + + - - - -
F8 5.0±0.10 + + + + + + + + + + + + + + + + + + + + + + + +
F9 5.0±0.20 + + + + + + + + + + + + + + + + + + + + + + + +
F10 - - - - - - - - - - - - - - - - - - - - - - - - -
F11 5.0±0.20 + + + + + + + + + + + + + + + + + + + + + + + +
F12 5.0±0.40 + + + + + + + + + + + + + + + + + + + + + + + +
 * Average value of three observations
(+) Indicate absence of floating      
                
(-) Indicate presence of floating
Discussion
o The formulations F1, F2, F3 were formulated by using methylcellulose in that F2, F3 showed the better floating in 
simulated gastric fluid pH 1.2 up to 24 hours.
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o The formulations F4, F5, F6 were formulated by using HPMC K 100M in that F5, F6 showed the better floating in simulated  
gastric fluid pH 1.2 up to 24 hours.
o The formulations F7, F8, F9 were formulated by using HPMC K 4M in that F8, F9 showed the better floating in simulated  
gastric fluid pH 1.2 up to 24 hours.
o The formulations F10 was formulated by using stearic acid it showed no  floating  property    in the simulated gastric fluid
       pH 1.2
o The formulations F11, F12 were formulated by using HPMC K 100M and stearic acid in that F11, F12 showed the better  
floating in simulated gastric fluid pH 1.2 up to 24 hours.
Table No.47 Floating Behaviours of Insoluble Floating Matrix Tablets (Simulated Gastric Fluid)
FC
*Lag time 
in seconds                                                                       *Duration of Floating Time hours
1 2 3 4 5 6 7 9 8 1
0
1
1
1
2
1
3
14 15 1
6
1
7
18 19 20 21 22 23 24
F13 - + + + + + + + + + + + + - - - - - - - - - - - -
F14 - + + + + + + + + + + + + - - - - - - - - - - - -
* Average value of three observations.
(-) Indicate absence of floating. 
(+) Indicate presence of floating.
Discussion
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o The Insoluble floating matrix tablets showed Floating behaviour in simulated gastric fluid pH 1.2 up to 12 hours in the 
form of disintegrated particles instead of intact tablet.
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Table No.48 Floating Behaviours of Combined Floating Matrix Tablets (Simulated Gastric Fluid pH 1.2)
FC
*Lag time 
in seconds                                                                       *Duration of Floating Time in hours
1 2 3 4 5 6 7 9 8 1
0
1
1
1
2
1
3
14 15 1
6
1
7
18 19 20 21 22 23 24
F15 4.5 ±0.60 + + + + + + + + + + + + + + + + + + + + + + + +
F16 5.0±0.82 + + + + + + + + + + + + + + + + + + + + + + + +
F17 4.8±0.14 + + + + + + + + + + + + + + + + + + + + + + + +
F18 5.0±0.56 + + + + + + + + + + + + + + + + + + + + + + + +
* Average value of three observations.
(-) Indicate absence of floating 
(+) Indicate presence of floating
Discussion
o The floating behaviours of Combined Floating Matrix Tablets showed better floating in simulated gastric fluid pH 1.2 for 
up to 24 hours.
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In vitro Drug Release Profile 
Dissolution profile for Hydrophilic Floating Matrix Tablets (Simulated Gastric 
Fluid pH 1.2)
Table No.49 Drug release Characteristics of Hydrophilic Floating Matrix Tablets  
(Simulated Gastric Fluid pH 1.2)
Time 
in 
hours
Methylcellulose HPMC K100M HPMC K 4M Effect of Stearic acid
Drug release in % Drug release in % Drug release in % Drug release in %
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
0.25 - - - - - - 12.50 - - - - -
0.50 02.99 02.00 01.75 03.37 01.25 - 18.75 05.00 01.23 10.41 1.25 -
0.75 11.70 10.75 10.00 12.50 05.00 05.00 28.75 22.50 06.18 18.75 4.50 -
1 17.90 17.00 16.75 25.00 21.25 12.50 53.75 36.25 12.50 27.08 7.35 2.55
2 29.18 25.40 19.25 33.75 28.75 18.75 63.75 43.75 30.00 40.75 10.00 5.05
3 36.60 36.60 30.45 47.50 40.00 23.75 80.50 62.50 40.00 57.50 15.85 8.75
4 51.60 45.39 50.15 71.25 50.00 32.50 99.00 78.75 48.75 76.04 20.00 12.55
5 95.60 64.60 63.60 87.50 61.25 38.75 - 81.25 62.50 81.66 23.75 16.25
6 - 79.00 79.00 98.50 76.25 46.25 - 98.20 76.25 98.08 27.50 18.75
7 - 97.50 85.35 - 83.75 53.75 - - 83.75 - 33.75 25.25
8 - - 92.25 - 97.25 58.70 - - 96.68 - 37.50 28.75
9 - - 99.02 - - 64.50 - - - - 41.25 37.55
10 - - - - - 75.00 - - - - 46.75 41.25
11 - - - - - 91.25 - - - - 50.00 43.75
12 - - - - - 96.42 - - - - 53.75 50.00
14 - - - - - - - - - - 58.90 56.45
16 - - - - - - - - - - 63.75 60.75
18 - - - - - - - - - - 73.75 66.25
20 - - - - - - - - - - 81.50 75.25
22 - - - - - - - - - - 88.75 86.00
24 - - - - - - - - - - 98.75 95.50
Discussion 
o The in vitro drug release of Hydrophilic Floating Matrix tablet without stearic acid 
showed their maximum amount of drug release in simulated gastric fluid pH 1.2 
before 12 hours.
o The  in vitro drug release of Hydrophilic Floating Matrix tablet  with stearic acid 
showed controlled drug release from the floating matrix tablet up to 24 
126
Figure No.20 In vitro Drug Release Profile of Hydrophilic Floating Matrix Tablets 
(Methylcellulose as polymer) in Simulated Gastric Fluid pH 1.2
Figure No.21 In vitro Drug Release Profile of Hydrophilic Floating Matrix Tablets 
(HPMC K 100M as polymer) in Simulated Gastric Fluid pH 1.2
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Figure No.22 In vitro Drug Release Profile of Hydrophilic Floating Matrix Tablets 
(HPMC K4 M as polymer) in Simulated Gastric Fluid pH 1.2
Figure No.23 Effect of Stearic acid in In vitro Drug Release Profile of Hydrophilic 
Floating Matrix Tablets in Simulated Gastric Fluid pH 1.2
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hours  and maintained their  floating in  the simulated  gastric  fluid pH 1.2 up to  the 
required period of time (24 hrs).
Table No.50 Drug release Characteristics of Insoluble Floating Matrix Tablets 
(Simulated Gastric Fluid pH 1.2)
Time in 
hours
Ethyl cellulose Eudragit RSPO
Drug release in % Drug release in %
F13 F14
0.25 - -
0.50 01.25 03.75
0.75 16.25 17.50
1 37.50 31.50
2 53.75 67.50
3 62.50 77.50
4 68.75 88.50
5 78.75 96.25
6 86.28 -
7 81.25 -
8 94.50 -
9 - -
10 - -
11 - -
12 - -
Discussion 
o The  in  vitro drug  release  of  Insoluble  Floating  Matrix  Tablets  showed  their 
maximum amount of drug release in simulated gastric fluid pH 1.2 before 12 hours.
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Figure No.24 In vitro Drug Release Profile of Insoluble Floating Matrix Tablets in 
Simulated Gastric Fluid pH 1.2
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Table No.51 Drug release Characteristics of Combined Floating Matrix Tablets (Simulated 
Gastric Fluid pH 1.2)
Time in 
hours
Ethylcllulose and
HPMC K 100M
Eudragit RSPO and 
HPMC K 100 M
Drug release in % Drug release in %
F15 F16 F17 F18
0.25 - - - -
0.50 01.25 - - -
0.75 06.25 03.75 05.00 01.25
1 12.50 08.40       10.25 12.50
2 18.75 13.75 27.45 20.81
3 30.50 24.75 42.50 31.25
4 37.46 31.25 52.50 42.50
5 50.00 42.50 67.80 50.00
6 65.00 51.25 75.00 56.25
7 68.75 56.20 81.25 63.75
8 81.25 66.40 93.75 73.75
9 95.60 89.20 96.62 88.50
10 - 96.80 - 98.00
11 - - - -
12 - - - -
Discussion 
o The  in  vitro drug  release  of  Combined  Floating  Matrix  Tablets  showed  their 
maximum amount of drug release in simulated gastric fluid pH 1.2 before 12 hours.
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Figure No.25 In vitro Drug Release Profile of Combined Floating Matrix Tablets in 
Simulated Gastric Fluid pH 1.2
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In vitro Drug Release Profile
Dissolution profile for Hydrophilic Floating Matrix Tablets in distilled water
Table No.52 Drug release Characteristics of Hydrophilic Floating Matrix Tablets 
(Distilled Water)
Time 
in 
hour
s
Methylcellulose HPMC K100M HPMC K 4M Effect of Stearic 
acid
Drug release in % Drug release in % Drug release in % Drug release in %
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
0.25 - - - - - - - - - - - -
0.50 10.4
1
09.3
3
10.0
0
05.0
0
02.5
0
- 21.25 06.2
5
03.7
1
12.5
0
- -
0.75 18.7
5
15.6
2
18.7
3
17.5
0
06.2
5
06.2
5
37.50 25.0
0
08.0
0
31.2
5
01.2
5
-
1 27.0
8
27.0
8
27.0
8
28.7
5
21.2
5
11.2
5
53.70 37.5
0
15.0
0
50.0
0
05.0
0
02.55
2 48.7
5
29.1
6
33.3
0
31.2
5
31.2
5
26.2
5
67.50 46.2
5
32.5
0
 1.25 10.0
0
05.05
3 57.5
0
37.5
0
43.7
6
46.2
5
51.2
5
31.2
5
97..5
0
63.7
5
42.5
0
80.2
5
17.5
0
08.75
4 76.0
4
55.1
9
48.7
5
75.0
0
65.0
0
37.5
0
- 81.2
5
51.2
4
86.2
5
20.0
0
12.50
5 91.6
6
72.9
1
57.0
0
98.7
5
78.7
5
42.5
0
- 93.7
5
65.0
0
98.7
5
23.7
5
16.25
6 95.0
8
77.0
8
69.3
7
- 88.7
5
48.7
5
- 99.3
5
80.0
0
- 27.5
0
18.75
7 - 85.4
2
77.5
0
93.7
5
55.0
0
- - 88.7
5
33.7
5
25.00
8 - 96.2
5
81.2
5
- 98.7
5
61.2
5
- 96.2
5
- 37.5
0
28.75
9 - - 95.6
5
- 68.7
5
- - 41.2
5
37.50
10 - - - - - 75.0
0
- - - 43.7
6
41.25
11 - - - - - 93.7
5
- - - - 50.0
0
43.75
12 - - - - - 98.7
0
- 53.7
5
50.00
14 - - - - - 56.2
5
56.25
16 - - - - - 63.7 60.00
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5
18 - - - - - 73.7
5
66.25
20 - - - - - 81.0
0
72.50
22 - - - - - 88.7
5
80.00
24 - - - - - - - - - - 98.7
5
92.50
Discussion
 
o The in vitro drug release of Hydrophilic Floating Matrix tablet without stearic acid 
showed their maximum amount of drug release in distilled water before  12 hours.
o The  in vitro drug release of Hydrophilic Floating Matrix tablet  with stearic acid 
showed controlled drug release from the floating matrix tablet up to 24
Figure No.26 In vitro Drug Release Profile of Hydrophilic Floating Matrix Tablets 
(Methylcellulose as polymer) in Distilled Water
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Figure No.27 In vitro Drug Release Profile of Hydrophilic Floating Matrix Tablets 
(HPMC K 100M as polymer) in Distilled Water 
Figure No.28 In vitro Drug Release Profile of Hydrophilic Floating Matrix Tablets 
(HPMC K4 M as polymer) in Distilled Water
Figure No.29 Effect of Stearic acid in In vitro Drug Release Profile of Hydrophilic 
Floating Matrix Tablets in Distilled Water
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o  hours and maintained their floating in the distilled water up to the required period 
of time (24 hrs).
Table No.53 Drug release Characteristics of Insoluble Floating Matrix Tablets (Distilled 
Water)
Time in 
hours
Ethyl cellulose Eudragit RSPO
Drug release in % Drug release in %
F13 F14
0.25 - -
0.50 03.75 05.00
0.75 17.52 21.25
1 42.50 37.50
2 53.75 67.50
3 64.68 75.00
4 75.00 83.75
5 81.25 96.25
6 92.50 -
7 97.80 -
8 - -
9 - -
In vitro Drug Release
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time in hours
%
 D
ru
g
 R
el
ea
se
F10
F11
F12
136
10 -
11 - -
12 - -
Discussion 
o The  in  vitro drug  release  of  Insoluble  Floating  Matrix  Tablets  showed  their 
maximum amount of drug release in distilled water before 12 hours.
Figure No.30 In vitro Drug Release Profile of Insoluble Floating Matrix Tablets in 
Distilled Water
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Table No.54 Drug release Characteristics of Combined Floating Matrix Tablets
(Distilled Water)
 
Time in 
hours
Ethylcllulose and 
HPMC K 100M
Eudragit RSPO and
HPMC K 100 M
Drug release in % Drug release in %
F15 F16 F17 F18
0.25 - - - -
0.50 02.50 - 01.25 -
0.75 07.50 05.00 06.25 01.25
1 13.50 11.25 16.25 11.25
2 21.20 16.25 28.75 18.25
3 32.50 27.50 37.50 30.00
4 40.00 33.35 41.25 41.25
5 51.25 43.00 48.75 48.75
6 62.50 53.75 62.50 55.00
7 71.20 58.75 68.75 61.25
8 96.75 68.75 80.50 72.50
9 - 77.50 97.75 81.25
10 - 95.81 - 96.75
11 - - - -
12 - - - -
Discussion 
o The  in  vitro drug  release  of  Combined  Floating  Matrix  Tablets  showed  their 
maximum amount of drug release in distilled water before 12 hours.
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Figure No.31 In vitro Drug Release Profile of Combined Floating Matrix Tablets in 
Distilled Water
In vitro Drug Release
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Time in hours
%
 D
ru
g
 R
e
le
a
s
e
F15
F16
F17
F18
139
Accelerated Stability Studies
TableNo.55 Stability Studies Reports as per ICH guidelines
Time 
period in 
weeks
Parameters
Weight in mg Hardness kg/cm2
Floating behaviours Drug 
Content %Lag time (sec) Duration (hrs)
0 day 150 5 5 24 98.90
1st week 150 5 5 24 98.78
2nd week 150 5 5 24 98.70
3rd week 151 4.8 5 24 98.66
4th week 151 4.8 5 24 97.89
Discussion 
The stability studies of the floating matrix tablets were studied as per ICH guidelines   for the 
period of one month and the percentage drug content of the formulation complied within 
the limit as per ICH guidelines (ICH limit 5%).
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8. Summary and Conclusion
 Several controlled oral drug delivery systems with prolonged gastric residence 
time  have  been  reported  such  as  Floating  system,  Swelling  system, 
Mucoadhesive system, High density system and other gastric emptying systems 
have been commonly used. Floating system has a lower density than the gastric 
fluid and thus remains buoyancy in the stomach, which retain in the stomach for 
a prolonged period of time.
 The objective  of this thesis work was planned to formulate the floating matrix 
tablet of Salbutamol sulphate by using different matrix forming material (like 
hydrophilic,  hydrophobic  and  combined  matrix  forming  material)  with  an 
extended drug release for administration as once daily dose.
 Hence this research work entitled  “Gastro retentive Drug Delivery System of 
Salbutamol sulphate: Formulation and its in vitro Evaluation” was under taken 
with the above object to achieve.
 The floating matrix tablet were formulated by using different matrix forming 
materials and grouped as following: 
1. Hydrophilic Floating Matrix Tablets
2. Insoluble Floating Matrix Tablets
3. Combined Floating Matrix Tablets
 The hydrophilic  floating  matrix  tablets  were formulated  by non-effervescent 
method by using different hydrocolloids like methyl cellulose, HPMC K100M, 
HPMC  K4M  and  their  floating  properties  and  in  vitro drug  release  were 
evaluated.  In  addition  to  the  polymer  stearic  acid  was  included  in  the 
hydrophilic floating matrix tablet and the effects of stearic acid in the in vitro 
drug release were evaluated.
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 The insoluble floating matrix tablets were formulated by effervescent method 
by using different matrix forming material like ethyl cellulose, Eudragit RSPO 
and their floating properties and in vitro drug release were evaluated. 
 The  combined  floating  matrix  tablets  were  formulated  by  non-effervescent 
method by using hydrophilic (HPMC K100M) and hydrophobic polymer (Ethyl 
cellulose, Eudragit RSPO) and their floating properties and in vitro drug release 
were evaluated. 
 The floating matrix tablets  were formulated by optimized formula during the 
trial on the basis of floating behaviors and in vitro drug release for 24 hours. 
 The floating matrix  tablets  were characterized by evaluation of bulk density, 
flow property, drug content, estimation of hardness and friability .The floating 
matrix  tablets  were  evaluated  for  their  floating  behaviors  and  in  vitro drug 
release  in  a  medium,  which  mimic  the  gastric  environment  like  simulated 
gastric  fluid  pH  1.2  and  water.  Different  trials  were  taken  to  optimize  the 
floating and  in  vitro drug release for prolonged period of time (i.e.  upto 24 
hours).
 Among the three different  floating matrix  tablet  formulation,  the hydrophilic 
floating matrix tablet  formulated with stearic acid showed satisfactory results 
for the parameters like  in vitro drug release and floating characteristics.  The 
objective of our project was satisfied.
 The effect of hardness and shape of floating matrix tablets on floating behaviors 
were studied by formulating floating matrix tablets with different hardness and 
shape, and their floating behaviors were evaluated. The floating matrix tablet 
which have hardness of about 5 kg/cm2 and round shaped tablets shows better 
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floating  than  highest  hardness  of  about  10  kg/cm2 and  oval  shape  as 
respectively, due to the decrease in porous nature of material were compressed 
at highest hardness 10kg/cm2. 
  The  stability  studies  of  the  selected  formulation  were  studied  as  per  ICH 
specification  their  drug  content,  and  physical  parameters  like  hardness  and 
floating behaviour were evaluated.
 All  the  process  parameters  and  results  of  formulations  were  found  to  be 
satisfactory  in  the  Hydrophilic  Floating  Matrix  tablets  with  stearic  acid  for 
Salbutamol sulphate as Gastro retentive drug delivery system.
 From this study it was concluded that “Gastro retentive Drug Delivery Systems 
as Floating Matrix Tablets” designed as three different  matrix tablet  such as 
Hydrophilic  Floating  Matrix  tablets,  Insoluble  Floating  Matrix  Tablets  and 
Combined Floating Matrix Tablets among them the Hydrophilic Floating Matrix 
Tablets with stearic acid of hardness about 5kg/cm2 and round shaped tablets 
could be suitable for floating and controlled the drug release form the dosage 
form for administration as once daily dose.
Future plan
• Further, the in vivo absorption studies by using suitable animal model will 
confirm their absorption of drug and floating behaviours of the dosage form.
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